Reshaping human antibodies for therapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1988-03

AUTHORS

L Riechmann, M Clark, H Waldmann, G Winter

ABSTRACT

A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. The reshaped human antibody is as effective as the rat antibody in complement and is more effective in cell-mediated lysis of human lymphocytes. More... »

PAGES

323-327

Journal

TITLE

Nature

ISSUE

6162

VOLUME

332

Related Patents

  • Apo-2 Receptor Polypeptides
  • Nucleic Acids Encoding Humanized Anti-Tag 72 Cc49 Antbodies
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Super Humanized Antibodies
  • Hybrid Antibodies
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Growth Factor Binding Constructs Materials And Methods
  • Bh3 Peptides And Method Of Use Thereof
  • Compositions And Methods For Cancer
  • Methods Of Administering/Dosing Anti-Rsv Antibodies For Prophylaxis And Treatment
  • Luca2 And Antibodies That Bind Thereto
  • Gitr-Binding Antibodies
  • Human Monoclonal Antibodies To Ctla-4
  • Therapy Targeting Flt4 (Veger-3) Expressed In Blood Vessels
  • Recombinant Tumor Specific Antibody And Use Thereof
  • Glycolipopeptide Antibodies
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Method For Treating Ige-Mediated Disorders
  • Pro 1384 Antibodies
  • Methods Of Optimizing Antibody Variable Region Binding Affinity
  • Pro 1384 Polypeptides
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Bgl4 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Recombinant Antibody And Antibody Fragment
  • Reshaped Human Antibody To Human Interleukin-8
  • Production Of Anti-Self Antibodies From Antibody Segment Repertoires And Displayed On Phage
  • Retargetting Antibodies
  • Humanized Antibodies
  • Production Of Multimeric Protein By Cell Fusion Method
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Matrix Metalloproteinases
  • Apo-2 Ligand
  • Substitutional Variants Of Apo-2 Ligand
  • Reshaped Human Anti-Hm 1.24 Antibody
  • Method For The Treatment Of Fibrosis
  • Antibodies To Dcr3 Polypeptide, A Tnfr Homolog
  • Catalytic Antibodies Against Cocaine And Methods Of Using And Producing Same
  • Humanized Immunoglobulins And Methods Of Making The Same
  • Humanised Antibodies
  • Methods Of Treating Hiv Infection Using Antibodies To The U2 Small Nuclear Ribonuclear Protein
  • Antibodies With Increased Binding Affinity
  • Anti-Ige Antibodies And Method Of Improving Polypeptides
  • Modified Antibodies With Human Milk Fat Globule Specificity And Uses
  • Anti-Psca Antibodies
  • Methods For Producing Members Of Specific Binding Pairs
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
  • Treatment For Inflammatory Bowel Disease With Vla-4 Blockers
  • Dna Molecules, Expression Vectors And Host Cells Expressing Antigenized Antibodies
  • Cytotoxic Drug Therapy
  • Immunoactive Peptides And Antibodies And Their Use In Anti-Allergy Treatment
  • Modified Antibody Variable Domains And Therapeutic Uses Thereof
  • Minimum Recognition Unit Of A Pem Mucin Tandem Repeat Specific Monoclonal Antibody
  • Catalytic Antibodies Against Cocaine
  • Recombinant Anti-Cd4 Antibodies For Human Therapy
  • Monoclonal Antibodies Against Tumor-Associated Antigens, Processes For The Preparation Thereof And The Use Thereof
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Klebsiella Antigens
  • Prevention And Treatment Of Amyloidgenic Disease
  • Tes7 And Antibodies That Bind Thereto
  • Estrogen Receptors And Methods Of Use
  • Compositions For Treating Amyloid Associated Diseases
  • Neutralizing Antibodies And Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (Pf4v1)
  • Method Of Isolating Cytotoxic Heterocomplex Associated With Multiple Sclerosis
  • Antibodies To Vla-1
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Methods For Producing Recombinant Proteins
  • Enhancing The Circulating Half-Life Of Antibody-Based Fusion Proteins
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Cd44 Polypeptides, Polynucleotides Encoding Same, Antibodies Directed Thereagainst And Method Of Using Same For Diagnosing And Treating Inflammatory Diseases
  • Nucleic Acids Encoding Anti-Factor D Antibodies
  • Multispecific Antibodies
  • Anti-Cd151 Antibodies And Their Use In The Treatment Of Cancer
  • Amyloid-Beta Binding Proteins
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Variants Of Humanized Anti-Carcinoma Mab Cc49
  • Arl-1 Specific Antibodies
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Methods Of Treating Rheumatoid Arthritis Using Antibodies To Matrix Metalloproteinase 9
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Fluorophore Chelated Lanthanide Luminescent Probes With Improved Quantum Efficiency
  • Hybrid Proteins
  • Methods For Treating Progressive Multiple Sclerosis
  • Diagnosis And Treatments Relating To Th2 Inhibition
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Simultaneous Imaging, Monitoring, And Therapy
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Cell-Permeable Probes For Identification And Imaging Of Sialidases
  • Method For The Treatment Of Inflammatory Disorders
  • Methods Of Treatment Using Antibodies Which Bind Il-17a And Il-17f
  • Crystal Structures Of Heterodimeric Fc Domains
  • T Cell Receptor-Like Antibodies Specific For A Wt1 Peptide Presented By Hla-A2
  • Pharmaceutical Composition For Treatment And Prevention Of Cancers
  • Therapeutic Combination And Methods Of Treatment With A Dll4 Antagonist And An Anti-Hypertensive Agent
  • Agents For Influenza Neutralization
  • Matrix Metalloproteinases
  • Apo-2 Ligand
  • Substitutional Variants Of Apo-2 Ligand
  • Reshaped Human Anti-Hm 1.24 Antibody
  • Anti-Psca Antibodies
  • Methods For Producing Members Of Specific Binding Pairs
  • Antibodies To Dcr3 Polypeptide, A Tnfr Homolog
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Retargetting Antibodies
  • Production Of Anti-Self Antibodies From Antibody Segment Repertoires And Displayed On Phage
  • Method For The Treatment Of Fibrosis
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
  • Treatment For Inflammatory Bowel Disease With Vla-4 Blockers
  • Catalytic Antibodies Against Cocaine
  • Monoclonal Antibodies Against Tumor-Associated Antigens, Processes For The Preparation Thereof And The Use Thereof
  • Reshaped Human Antibody To Human Interleukin-8
  • Catalytic Antibodies Against Cocaine And Methods Of Using And Producing Same
  • Humanized Immunoglobulins And Methods Of Making The Same
  • Recombinant Anti-Cd4 Antibodies For Human Therapy
  • Anti-Ige Antibodies And Method Of Improving Polypeptides
  • Bispecific Antibodies Against Cd3 And Bcma
  • Minimum Recognition Unit Of A Pem Mucin Tandem Repeat Specific Monoclonal Antibody
  • Methods Of Treating Hiv Infection Using Antibodies To The U2 Small Nuclear Ribonuclear Protein
  • Modified Antibody Variable Domains And Therapeutic Uses Thereof
  • Dna Molecules, Expression Vectors And Host Cells Expressing Antigenized Antibodies
  • Cytotoxic Drug Therapy
  • Humanised Antibodies
  • Method For The Treatment Of Inflammatory Disorders
  • Anti-Hepcidin Antibodies And Uses Thereof
  • Albumin Binding Antibodies And Binding Fragments Thereof
  • Cell-Permeable Probes For Identification And Imaging Of Sialidases
  • Automatic Image Playback
  • Immunoactive Peptides And Antibodies And Their Use In Anti-Allergy Treatment
  • Hiv Immunotherapeutics
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Methods For The Therapy Of Inflammatory Bowel Disease Using A Type-1 Interferon Antagonist
  • Shortened Tetranectin-Apolipoprotein A-I Fusion Protein, A Lipid Particle Containing It, And Uses Thereof
  • Humanised Antibodies
  • Antibody Constructs With Cdr Switched Variable Regions
  • Dual Specific Binding Proteins Directed Against Il-1 And/Or Il-17
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Antibody Molecules Specific To Human Tumor Necrosis Factor Alpha
  • Antibodies To Cytosolic Peptides
  • Pharmaceutical Compositions Containing Sc(Fv)2
  • Biological Products
  • Bgl5 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Antibodies Specific For Hyperphosphorylated Tau And Methods Of Use Thereof
  • Pharmaceutical Composition For Treatment And/Or Prophylaxis Of Cancer
  • Interleukin-13 Binding Proteins
  • Rm2 Antigens And Use Thereof
  • Inhibitors Of Platelet Binding
  • Anti-Pmel17 Antibodies And Immunoconjugates
  • Extracellular Matrix Metalloproteinase Inducer (Emmprin) Peptides And Binding Antibodies
  • Single-Chain Antibodies And Other Heteromultimers
  • Methods Of Treating Rheumatoid Arthritis Using Antibodies To Matrix Metalloproteinase 9
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Fluorophore Chelated Lanthanide Luminescent Probes With Improved Quantum Efficiency
  • Influenza Treatment And/Or Characterization, Human-Adapted Ha Polypeptides; Vaccines
  • Anti-Hepcidin Antibodies And Uses Thereof
  • Diagnostic Antibody Assay
  • Polynucleotides Encoding Anti-Amyloid Beta Monoclonal Antibodies
  • Anti-Vegf Antibodies
  • Glycan-Interacting Compounds
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Pancreatic Cancer
  • Cancer Therapy
  • Compositions And Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Antibodies To Madcam
  • Heterodimeric Antibodies To Cd3 X Cd123
  • Method And Composition For Treatment Of Renal Failure With Antibodies And Their Equivalents As Partial Or Complete Replacement For Dialysis
  • Treatment Of Amyloidogenic Diseases
  • Therapeutic Combination And Methods Of Treatment With A Dll4 Antagonist And An Anti-Hypertensive Agent
  • Methods For Inactivating Viruses During A Protein Purification Process
  • Humanized Anti-Cd11a Antibodies
  • Assays For Detecting Antibodies Specific To Therapeutic Anti-Ige Antibodies And Their Use In Anaphylaxis
  • Humanized Immunoglobulins
  • Methods For Identifying Inhibitors Of Neuronal Degeneration
  • Method For Making Humanized Antibodies
  • Tlr3 Binding Agents
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Human Monoclonal Antibodies To Ctla-4
  • Human Il-23 Antigen Binding Proteins
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • T Cell Receptor-Like Antibodies Specific For A Wt1 Peptide Presented By Hla-A2
  • Filip1l Nucleic Acid Fragments
  • Human Protein Tyrosine Phosphatase Inhibitors And Method Of Use
  • Antibodies To Carcinoembryonic Antigen-Related Cell Adhesion Molecule (Ceacam)
  • Anti-Trop-2 Antibody-Drug Conjugates And Uses Thereof
  • Anti-Vegf Antibodies
  • Methods Of Treating Cancer By Administering Anti-Gpr49 Antibodies
  • Infectious Clone Of Human Parvovirus B19 And Methods
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Targeted Delivery To Legumain-Expressing Cells
  • Epha2 As A Therapeutic Target For Cancer
  • Recombinant Protein Production In A Human Cell Comprising At Least One E1 Protein Of Adenovirus
  • Mfap4 As A Marker For Regulatory Cells And Anti-Cancer Cells
  • Methods For Producing Humanized Antibodies And Improving Yield Of Antibodies Or Antigen Binding Fragments In Cell Culture
  • Antibodies To Oncostatin M Receptor
  • Transferrin Receptor Antibodies
  • Monoclonal Antibody
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Method For Multiple Chemokine Receptor Screening For Antagonists Using Ram Assay
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
  • Production Of A Multimeric Protein By Cell Fusion Method
  • Antibodies Against The Pro4401 Polypeptide
  • Method For Assessing Metastatic Properties Of Breast Cancer
  • Humanized Antibody Against Human Tissue Factor (Tf) And Process Of Production Of The Humanized Antibody
  • Humanized Antibody Against S-Surface Antigen Of Hepatitis B Virus
  • Il-1 Binding Proteins
  • Chimeric Ospa Proteins And Methods Of Use Thereof
  • Antibody Specifically Binding To Insulin-Like Growth Factor-1
  • Pharmaceutical Composition For Treatment And/Or Prophylaxis Of Cancer
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Glycan-Interacting Compounds
  • Enzymatic Conjugation Of Polypeptides
  • Humanized Antibodies To Fc Receptors For Immunoglobulin G On Human Mononuclear Phagocytes
  • Humanized Immunoglobulins
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Anti-Clusterin Antibodies And Antigen Binding Fragments And Their Use To Reduce Tumor Volume
  • Cadherin-11 Inhibitors And Methods Of Use Thereof
  • Cbh1 Homologs And Varian Cbh1 Cellulase
  • Methods For Enhanced Protein Production
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Glycopeptide And Uses Thereof
  • Il-1 Binding Proteins
  • Epha2 As A Therapeutic Target For Cancer
  • Method Of Forming A Fiber Made Of Peptide Nanostructures
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Human Cdr-Grafted Antibody And Antibody Fragment Thereof
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Antibodies To Human Il-1Β
  • Assay For Identifying Antibody Producing Cells
  • Cd44 Polypeptides, Polynucleotides Encoding Same, Antibodies Directed Thereagainst And Method Of Using Same For Diagnosing And Treating Inflammatory Diseases
  • Monoclonal Antibody Inducing Apoptosis
  • Targeted Delivery To Legumain-Expressing Cells
  • Infectious Clone Of Human Parvovirus B19 And Methods
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Mfap4 As A Marker For Regulatory Cells And Anti-Cancer Cells
  • Methods For Producing Humanized Antibodies And Improving Yield Of Antibodies Or Antigen Binding Fragments In Cell Culture
  • Antibodies To Oncostatin M Receptor
  • Transferrin Receptor Antibodies
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Method And Composition For Treatment Of Renal Failure With Antibodies And Their Equivalents As Partial Or Complete Replacement For Dialysis
  • Treatment Of Amyloidogenic Diseases
  • Aβ Conformer Selective Anti-Aβ Globulomer Monoclonal Antibodies
  • Carriers For Improved Drug Delivery
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Polarization Sensitive Optical Coherence Tomography System
  • Anti-Pd-L1 Antibodies, Compositions And Articles Of Manufacture
  • Compositions And Methods For Simultaneous Bivalent And Monovalent Co-Engagement Of Antigens
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Method For Inducing Cell Death In Acute Lymphoblastic Leukemic System Cells
  • Nucleic Acid Encoding Chimeric Il-1 Receptor Type I Antagonists
  • Notch1 Binding Agents And Methods Of Use Thereof
  • Methods For Treating Vascular Leak Syndrome
  • Amyloid-Beta Binding Proteins
  • Systems For Correcting Distortions In A Medical Image And Methods Of Use Thereof
  • Rsv Specific Binding Molecule
  • Modified Polynucleotides Encoding Granulysin
  • Stimulus Responsive Polymers For The Purification Of Biomolecules
  • Methods Of Treating Cancer By Administering Anti-Gpr49 Antibodies
  • Reagents And Methods For Detecting A Polymorphic Protein
  • Antibody-Drug Conjugates And Uses Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Modified Polynucleotides For Treating Galactosylceramidase Protein Deficiency
  • Gdf-15 As A Diagnostic Marker For Melanoma
  • Combination Therapy Using Inhibitors Of Human Growth And Differentiation Factor 15 (Gdf-15) And Immune Checkpoint Blockers
  • Anti-B7-H4 Antibodies And Immunoconjugates
  • Substances And Their Uses
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Method For Making Humanized Antibodies
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Filip1l Nucleic Acid Fragments
  • Il-17 Binding Proteins
  • Epha2 As A Therapeutic Target For Cancer
  • Recombinant Protein Production In A Human Cell Comprising At Least One E1 Protein Of Adenovirus
  • Anti-Idiotypic Antibody Neutralizing The Inhibitor Activity Of A Factor Viii Inhibitor Antibody
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Automatic Stent Detection
  • Rapid Clearance Of Antigen Complexes Using Novel Antibodies
  • Antibodies With Modified Isoelectric Points
  • Methods For Generating Radioimmunoconjugates
  • Ddr1-Binding Agents And Methods Of Use Thereof
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Fluorophore Chelated Lanthanide Luminescent Probes With Improved Quantum Efficiency
  • Compositions And Methods For Diagnosing And Treating Phenylketonuria (Pku)
  • Calicheamicin Derivative-Carrier Conjugates
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Immunocytokine Sequences And Uses Thereof
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Single Chain Multivalent Binding Proteins With Effector Function
  • Humanized Antibodies To Amyloid Beta
  • Humanized Antibodies Against Light And Uses Thereof
  • Peptides Protective Against S. Pneumoniae And Compositions, Methods And Uses Relating Thereto
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Glycan-Interacting Compounds
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Immunocytokine Sequences And Uses Thereof
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Single Chain Multivalent Binding Proteins With Effector Function
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Combination Of Fcγriib-Specific Antibodies And Cd20-Specific Antibodies And Methods Of Use Thereof
  • Humanized Antibodies To Amyloid Beta
  • Compositions And Methods For Diagnosing And Treating Phenylketonuria (Pku)
  • Rapid Clearance Of Antigen Complexes Using Novel Antibodies
  • Antibodies With Modified Isoelectric Points
  • Methods For Generating Radioimmunoconjugates
  • Vessel Assembly
  • Human Monoclonal Antibodies To Ctla-4
  • Immunoglobulins Insertions, Deletions, And Substitutions
  • Immunoglobulin Insertions, Deletions, And Substitutions
  • Amyloid-Beta Binding Proteins
  • Bi-Specific Monovalent Diabodies That Are Capable Of Binding Cd123 And Cd3, And Uses Thereof
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Interleukin-13 Binding Proteins
  • Methods Of Treating Ocular Disease Associated With Amyloid-Beta-Related Pathology Using An Anti-Amyloid-Beta Antibody
  • Telescopic Side Port Catheter Device With Imaging System And Method For Accessing Side Branch Occlusions
  • Method For Inducing Cell Death In Acute Lymphoblastic Leukemic System Cells
  • Nucleic Acid Encoding Chimeric Il-1 Receptor Type I Antagonists
  • Systems For Correcting Distortions In A Medical Image And Methods Of Use Thereof
  • Glycopeptide And Uses Thereof
  • Il-1 Binding Proteins
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Anti-Idiotypic Antibody Neutralizing The Inhibitor Activity Of A Factor Viii Inhibitor Antibody
  • Il-17 Binding Proteins
  • Antibodies To Human Il-1Β
  • Assay For Identifying Antibody Producing Cells
  • Method Of Forming A Fiber Made Of Peptide Nanostructures
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Antibody-Drug Conjugates And Uses Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Compositions And Methods For Simultaneous Bivalent And Monovalent Co-Engagement Of Antigens
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Rsv Specific Binding Molecule
  • Modified Polynucleotides Encoding Granulysin
  • Stimulus Responsive Polymers For The Purification Of Biomolecules
  • Humanized Antibody Against S-Surface Antigen Of Hepatitis B Virus
  • Production Of A Multimeric Protein By Cell Fusion Method
  • Antibodies Against The Pro4401 Polypeptide
  • Substances And Their Uses
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Method For Making Humanized Antibodies
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Human Cdr-Grafted Antibody And Antibody Fragment Thereof
  • Reagents And Methods For Detecting A Polymorphic Protein
  • Anti-Clusterin Antibodies And Antigen Binding Fragments And Their Use To Reduce Tumor Volume
  • Cadherin-11 Inhibitors And Methods Of Use Thereof
  • Cbh1 Homologs And Varian Cbh1 Cellulase
  • Methods For Enhanced Protein Production
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Epha2 As A Therapeutic Target For Cancer
  • Compositions Comprising Chimeric Ospa Molecules And Methods Of Use Thereof
  • Amyloid-Beta Binding Proteins
  • Camptothecin Conjugates Of Anti-Cd22 Antibodies For Treatment Of B Cell Diseases
  • Antibodies To Receptor For Advanced Glycation End Products (Rage) And Uses Thereof
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Method For The Treatment Of Inflammatory Disorders
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Peptide Nanostructures Encapsulating A Foreign Material And Method Of Manufacturing Same
  • Neuropilin Antagonists
  • Multivalent Antibodies And Uses Therefor
  • Human Il-23 Antigen Binding Proteins
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Antibodies That Bind Cd40 And Methods Of Treating Cancer And Enhancing Immune Responses
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Human Fgf Receptor And Β-Klotho Binding Proteins
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Mhc-Peptide Complex Binding Ligands
  • Anti-Ngf Antibodies And Methods Using Same
  • Combination Of Anti-Ep-Cam Antibody With A Chemotherapeutic Agent
  • Interferon Alpha Receptor 1 Antibodies And Their Uses
  • Dna Encoding Antibody Molecules Having Specificity For Human Il-6
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Engineered Anti-Il-23p19 Antibodies
  • Protein Kinase Ck2 Gene Mutations, Amplifications And Polymorphisms In Human Cancers And Methods Of Use
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Fc Region-Containing Polypeptides That Exhibit Improved Effector Function Due To Alterations Of The Extent Of Fucosylation, And Methods For Their Use
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Designed Deimmunized Monoclonal Antibodies For Protection Against Hiv Exposure And Treatment Of Hiv Infection
  • Expression Cassette And Vector For Transient Or Stable Expression Of Exogenous Molecules
  • Treatment For Asthma With Α4-Specific Antibodies
  • Modified Polynucleotides Encoding Apoptosis Inducing Factor 1
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections
  • Prevention And Treatment Of Amyloidogenic Disease
  • Antibodies To Matrix Metalloproteinase 9
  • Synthetic Peptide Constructs For The Diagnosis And Treatment Of Periodontitis Associated With Porphyromonas Gingivalis
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells
  • Interferon Alpha Receptor 1 Antibodies And Their Uses
  • Anti-Vegf Antibodies
  • Variants Of Humanized Anti-Carcinoma Mab Cc49
  • Antibodies Directed Against Amyloid-Beta Peptide And Nucleic Acids Encoding Same
  • Methods Compositions And Articles Of Manufacture For Modulating Bone Growth
  • Antibodies For Inhibiting Blood Coagulation And Methods Of Use Thereof
  • Apo-2 Receptor Polypeptides
  • Isolated Stra6 Polypeptides
  • Methods Of Treating Vascular Inflammatory Pathology Using Anti-Tnf Antibodies And Fragments Thereof
  • Antibodies That Bind To Cancer-Associated Antigen Cd46 And Methods Of Use Thereof
  • Ultra High Affinity Neutralizing Antibodies
  • Mhc-Peptide Complex Binding Ligands
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Peptide Nanostructures And Methods Of Generating And Using The Same
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Binding Polypeptides And Uses Thereof
  • Cells Expressing Anti-Gd2 Antibodies And Methods Related Thereto
  • Anti-H7cr Antibodies
  • Antibodies To C-Met
  • Antibody Molecules Having Binding Specificity For Human Il-13
  • Humanized Aβ Antibodies For Use In Improving Cognition
  • Cell Culture Compositions
  • Anti-Pd-L1 Antibodies And Uses Therefor
  • Klebsiella Antigens
  • Antibodies To Lymphotoxin-Alpha
  • Fgf21 Mutants Multimers And Uses Thereof
  • Phosphopeptide Compositions And Anti-Phosphopeptide Antibody Compositions And Methods Of Detecting Phosphorylated Peptides
  • Production Of Secreted Therapeutic Antibodies In Microalgae
  • Modified Binding Molecules Comprising Connecting Peptides
  • Peptide Ligands For G-Protein Coupled Receptors
  • Methods Of Determining Patient Response By Measurement Of Her-3
  • Anti-B7-H4 Antibodies And Their Uses
  • Method For Treating The Th2-Mediated Disease
  • Genetically Modified Human Natural Killer Cell Lines
  • Homeobox Gene
  • Chimeric Polypeptides And Uses Thereof
  • Anti-Aβ Oligomer Humanized Antibody
  • Compounds
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Neuropilin Antagonists
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Human Antibodies Specific For Gastrin Materials And Methods
  • Bgl6 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Compositions And Methods For Immunotherapy Of Cancer And Infectious Diseases
  • Antibodies That Bind To Epha2 And Methods Of Use Thereof
  • Compositions And Methods For Binding Lysophosphatidic Acid
  • Combination Of Anti-Ep-Cam Antibody With A Chemotherapeutic Agent
  • Anti-Ngf Antibodies And Methods Using Same
  • Genetically Modified Human Natural Killer Cell Lines
  • Complement Inhibition For Improved Nerve Regeneration
  • Enhancement Of Natural Killer (Nk) Cell Proliferation And Activity
  • Amyloid Beta(1-42) Oligomers, Derivatives Thereof And Antibodies Thereto, Methods Of Preparation Thereof And Use Thereof
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Heterodimeric Proteins
  • Anticoagulant Antidotes
  • Crystal Structures Of Heterodimeric Fc Domains
  • Therapeutic Vitamin D Conjugates
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Multispecific Antibodies
  • Lowered Affinity Antibodies And Methods Of Making The Same
  • Human Inkt Cell Activation Using Glycolipids With Altered Glycosyl Groups
  • Methods For Treating, Diagnosing, And Monitoring Lupus
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Method Of Treatment For Leukemia Using An Anti-Il1rap Antibody
  • Method Of Treating A Solid Tumor With Il1rap Antibodies
  • Variant Enzymes
  • Methods For Modifying Human Antibodies By Glycan Engineering
  • Neutralizing Monoclonal Antibodies Against The Nogo-66 Receptor (Ngr) And Uses Thereof
  • Formulation For Anti-Α4Β7 Antibody
  • Amyloid-Beta Binding Proteins
  • Optimized Variants Of Anti-Vegf Antibodies And Methods Of Treatment Thereof By Reducing Or Inhibiting Angiogenesis
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Anti-B7-H4 Antibodies And Immunoconjugates
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Anti-Alpha V Beta 6 Antibodies And Uses Thereof
  • Cross-Reactive Staphylococcus Aureus Antibody
  • Time-Resolved Laser-Induced Fluorescence Spectroscopy Systems And Uses Thereof
  • Agents, Uses And Methods For The Treatment Of Synucleinopathy
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Dual Fc Antigen Binding Proteins
  • Isolated Dna Sequences Encoding, And Methods For Making, Antibody Molecules Having Binding Specificity For Human Il-13
  • Method For The Selection Of Antibodies Against Bcma
  • Biological Materials And Uses Thereof
  • Trem2 Cleavage Modulators And Uses Thereof
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Modified Polynucleotides Encoding Cited4
  • Protein Formulation
  • Modified Polynucleotides For The Production Of Nuclear Proteins
  • Methods And Kits For Diagnosing Tumorigenicity
  • Methods For Expressing And Recovering Human Monoclonal Antibodies To Ctla-4
  • Structural Isomers Of Sc(Fv)2
  • Anti-Gpr49 Monoclonal Antibodies
  • Modified Polynucleotides Encoding Septin-4
  • Automatic Calibration Systems And Methods Of Use
  • Single-Chain Multiple Antigen-Binding Molecule, Its Preparation And Use
  • Gene Constructs Coding For Cd40-Binding Activating Antibodies
  • Compositions And Methods For Cancer
  • Recombinant Anti-Vla4 Antibody Molecules
  • Ultra High Affinity Neutralizing Antibodies
  • Isolated Stra6 Polypeptides
  • Methods Of Treating Vascular Inflammatory Pathology Using Anti-Tnf Antibodies And Fragments Thereof
  • Antibodies That Bind To Cancer-Associated Antigen Cd46 And Methods Of Use Thereof
  • Antibodies Directed Against Amyloid-Beta Peptide And Nucleic Acids Encoding Same
  • Peptides Directed For Diagnosis And Treatment Of Amyloid-Associated Disease
  • Method For Treating The Th2-Mediated Disease
  • Lowered Affinity Antibodies And Methods Of Making The Same
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Multispecific Antibodies
  • Complement Inhibition For Improved Nerve Regeneration
  • Therapeutic Vitamin D Conjugates
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Binding Polypeptides And Uses Thereof
  • Cells Expressing Anti-Gd2 Antibodies And Methods Related Thereto
  • Humanized Aβ Antibodies For Use In Improving Cognition
  • Genetically Modified Human Natural Killer Cell Lines
  • Anti-B7-H4 Antibodies And Their Uses
  • Anti-Pd-L1 Antibodies And Uses Therefor
  • Homeobox Gene
  • Chimeric Polypeptides And Uses Thereof
  • Peptide Ligands For G-Protein Coupled Receptors
  • Methods Of Determining Patient Response By Measurement Of Her-3
  • Neuropilin Antagonists
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Compounds
  • Human Antibodies Specific For Gastrin Materials And Methods
  • Bgl6 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Anti-Aβ Oligomer Humanized Antibody
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Compositions And Methods For Immunotherapy Of Cancer And Infectious Diseases
  • Antibody Molecules Having Binding Specificity For Human Il-13
  • Modified Binding Molecules Comprising Connecting Peptides
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Anti-H7cr Antibodies
  • Antibodies To C-Met
  • Fgf21 Mutants Multimers And Uses Thereof
  • Phosphopeptide Compositions And Anti-Phosphopeptide Antibody Compositions And Methods Of Detecting Phosphorylated Peptides
  • Cell Culture Compositions
  • Production Of Secreted Therapeutic Antibodies In Microalgae
  • Klebsiella Antigens
  • Antibodies To Lymphotoxin-Alpha
  • Anti-Cmet Antibody
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Humanized Antibodies That Recognize Beta Amyloid Peptide
  • Hcv Ns3 Recombinant Antigens And Mutants Thereof For Improved Antibody Detection
  • Polynucleotides Encoding Anti-Gd2 Antibodies
  • Method For Making Heteromultimeric Molecules
  • Hydrazinyl-Indole Compounds And Methods For Producing A Conjugate
  • Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes
  • Anti-Cea Antibodies
  • Chimeric Ospa Genes, Proteins And Methods Of Use Thereof
  • Anti-Mesothelin Antibodies
  • Methods Of Modulating Immune Function
  • Bh3 Peptides And Method Of Use Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Compositions And Methods For Growth Factor Modulation
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Method For The Treatment Of Amyloidoses
  • Humanized Immunoglobulin Reactive With Α4Β7 Integrin
  • Methods For Identifying Inhibitors Of Neuronal Degeneration
  • Anti-Dota Antibody
  • Cytokine Receptors And Nucleic Acids Encoding The Same
  • Efficient Synthesis Of Protein-Oligonucleotide Conjugates
  • Methods For Identifying Inhibitors Of Cytokinesis Using Cyk-4 Proteins
  • Humanised Antibodies
  • Bispecific Molecules Cross-Linking Itim And Itam For Therapy
  • Matrix Metalloproteinase Polypeptide
  • Anti Cxcr4 Antibodies And Their Use For The Treatment Of Cancer
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Humanized Fcγriib-Specific Antibodies And Methods Of Use Thereof
  • Tes7 And Antibodies That Bind Thereto
  • Enzymatic Conjugation Of Antibodies
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Anti-Htra1 Antibodies And Methods Of Use
  • A Method For Reducing The Immunogenicity Of Antibody Variable Domains
  • Humanized Cdr-Grafted Anti-Icam-1 Antibodies, Methods Of Preparation And Usage Thereof
  • Humanized Chimeric Antibody Directed Against Ganglioside Gd3
  • Apo-2-Receptor
  • Recombinant Anti-Vla-4 Antibody Molecules
  • Methods For Detecting Prostate Stem Cell Antigen Protein
  • Apoptosis Inducing Molecule Ii And Methods Of Use
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Method For Producing Polymers Having A Preselected Activity
  • Catalytic Antibodies Against Cocaine And Methods Of Using And Producing Same
  • Production Of Anti-Self Bodies From Antibody Segment Repertories And Displayed On Phage
  • Antibodies To The Antigen Campath-1
  • Isolated Peptide Or Polypeptide Of The Extracellular Portion Of The Human Interferon Receptor (Ifn-R).
  • Method For Making Humanized Antibodies
  • Variants Of Humanized Anti Carcinoma Monoclonal Antibody Cc49
  • Cdna Encoding A Gene Bog (B5t Over-Expressed Gene) And Its Protein Product
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Cytotoxic Drug Therapy
  • Nucleic Acids Encoding Interleukin-5 Specific Recombinant Antibodies
  • Method For Producing Polymers Having A Preselected Activity
  • Antibodies To The Antigen Campath-1
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Humanized Immunoglobulins
  • Anti-Aβ Globulomer 7c6 Antibodies
  • Hcv Core Lipid Binding Domain Monoclonal Antibodies
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
  • Chemically Modified Binding Protein
  • Anticoagulant Antidotes
  • Humanized Fcγriib-Specific Antibodies And Methods Of Use Thereof
  • Tes7 And Antibodies That Bind Thereto
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Method For The Treatment Of Amyloidoses
  • Bispecific Molecules Cross-Linking Itim And Itam For Therapy
  • Modified Polynucleotides For Treating Protein Deficiency
  • Isolated Peptide Or Polypeptide Of The Extracellular Portion Of The Human Interferon Receptor (Ifn-R).
  • Method For Making Humanized Antibodies
  • Anti Cxcr4 Antibodies And Their Use For The Treatment Of Cancer
  • Method For The Treatment Of Inflammatory Disorders
  • Amyloid-Beta Globulomer Antibodies
  • Nucleic Acid Encoding Anti-Ige Antibodies
  • Humanized Immunoglobulin Reactive With Α4Β7 Integrin
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Il-1 Binding Proteins
  • Treatment Methods Using C-Met Antibodies
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid And Compositions Containing The Same
  • Cd40 Ligand Adjuvant For Respiratory Syncytial Virus
  • Method For Producing Polymers Having A Preselected Activity
  • Iconic Communication
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Binding Proteins That Bind To Human Fgfr1c, Human Β-Klotho And Both Human Fgfr1c And Human Β-Klotho
  • Compositions And Methods Using Same For Treating Amyloid-Associated Diseases
  • Hybrid Proteins
  • Cd3 Specific Recombinant Antibody
  • Human M2e Peptide Immunogens
  • Prevention, Treatment And Diagnosis Of P. Gingivalis Infection
  • Dna Encoding Antibody Molecules Having Specificity For Human Il-6
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Engineered Anti-Il-23p19 Antibodies
  • Protein Kinase Ck2 Gene Mutations, Amplifications And Polymorphisms In Human Cancers And Methods Of Use
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Fc Region-Containing Polypeptides That Exhibit Improved Effector Function Due To Alterations Of The Extent Of Fucosylation, And Methods For Their Use
  • Bispecific Antibodies Against Human Tweak And Human Il17 And Uses Thereof
  • Treatment For Asthma With Α4-Specific Antibodies
  • Humanized Anti-Cmet Antibodies
  • Therapeutic Agent For Cachexia
  • Biological Products
  • Cytotoxicity Mediation Of Cells Evidencing Surface Expression Of Cd44
  • Anti-Her2 Antibody Variants
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Antibodies Against Human Tweak And Uses Thereof
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Genetically Modified Human Natural Killer Cell Lines
  • Monoclonal Antibody To A Human Mdr1 Multidrug Resistance Gene Product, And Uses
  • Compositions And Methods For Treatment Of Cancer
  • Antibody Specificity Transfer Using Minimal Essential Binding Determinants
  • Nucleic Acid Molecules Encoding Minimally Immunogenic Variants Of Sdr-Grafted Humanized Antibody Cc49
  • Internalizing Anti-Cd74 Antibodies And Methods Of Use
  • Compositions Capable Of Specifically Binding Particular Human Antigen Presenting Molecule/Pathogen-Derived Antigen Complexes And Uses Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Antibodies Against Platelet-Derived Growth Factor (Pdgf)
  • Methods And Compositions For Screening And Detecting Biomarkers
  • Method Of Treating Type 1 Diabetes By Administering Nkp46 Polypeptide
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Antibodies To Matrix Metalloproteinase 9
  • Synthetic Peptide Constructs For The Diagnosis And Treatment Of Periodontitis Associated With Porphyromonas Gingivalis
  • Modified Polynucleotides Encoding Apoptosis Inducing Factor 1
  • High Concentration Antibody And Protein Formulations
  • Prevention And Treatment Of Amyloidogenic Disease
  • Method For Making Heteromultimeric Molecules
  • Hydrazinyl-Indole Compounds And Methods For Producing A Conjugate
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Anti-Htra1 Antibodies And Methods Of Use
  • Reactive Labelling Compounds And Uses Thereof
  • Interferon Receptor 1 Antibodies And Their Uses
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Methods Of Treating Inflammatory Disorders Using High Concentration Natalizumab Compositions
  • Antibodies To The E1 Extracellular Loop Of Ion Channels
  • Reducing The Immunogenicity Of Fusion Proteins
  • Biological Materials And Uses Thereof
  • Microporous Materials, Methods Of Making, Using, And Articles Thereof
  • Antibodies To Human Il-1Β
  • Polynucleotides Encoding Humanized Anti-Factor D Antibodies
  • Treatment Of Amyloidogenic Diseases
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Combination Therapy With Anti-Cd74 And Anti-Cd20 Antibodies Provides Enhanced Toxicity To B-Cell Diseases
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Methods For Killing Psma-Expressing, Taxane-Resistant Cancer Cells
  • Protective Proteins Of S. Agalactiae, Combinations Thereof And Methods Of Using The Same
  • Fgf 21 Polypeptides Comprising Two Or More Mutations And Uses Thereof
  • Compositions For The Prevention And Treatment Of Smallpox
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Use Of Interleukin-4 Antibodies And Compositions Thereof
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Anti-Lgr5 Antibodies And Immunoconjugates
  • Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
  • Polynucleotides Encoding Humanized Anti-Factor D Antibodies
  • Treatment Of Amyloidogenic Diseases
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Trivalent, Bispecific Antibodies
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Anti-Igf-Ir Antibodies And Uses Thereof
  • Determining The Capability Of A Test Compound To Affect Solid Tumor Stem Cells
  • Antibodies To Vla-1
  • Antibodies To Apo-2 Receptor Polypeptides
  • Interferon Receptor 1 Antibodies And Their Uses
  • Anti-Aβ Oligomer Humanized Antibody
  • Cytotoxicity Mediation Of Cells Evidencing Surface Expression Of Cd44
  • Compositions And Methods For Treating Pigmentary Conditions And Melanoma
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Methods Of Treating Inflammatory Disorders Using High Concentration Natalizumab Compositions
  • Vegf Binding Antibodies
  • Porcine Circovirus Type 2 Vaccines
  • Combination Therapy With Anti-Cd74 And Anti-Cd20 Antibodies Provides Enhanced Toxicity To B-Cell Diseases
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Methods For Killing Psma-Expressing, Taxane-Resistant Cancer Cells
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Use Of Interleukin-4 Antibodies And Compositions Thereof
  • Anti-Vegf Antibodies
  • Method For Making Heteromultimeric Molecules
  • Polypeptides And Use Thereof
  • Modified Polynucleotides For The Production Of Proteins Associated With Human Disease
  • Method Of Overcoming Therapeutic Limitations Of Nonuniform Distribution Of Radiopharmaceuticals And Chemotherapy Drugs
  • Antibodies To Vla-1
  • Bispecific Antibodies Comprising A Disulfide Stabilized-Fv Fragment
  • Modified Immunoglobulin Molecules That Specifically Bind Human Vegf And Dll4
  • Method For Detecting Cancer Via Measurement Of Caprin-1 Expression Level
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Il-1 Binding Proteins
  • Il-1 Binding Proteins
  • Methods And Compositions For The Treatment Of Proliferative And Pathogenic Diseases
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Bispecific Molecules That Are Immunoreactive With Immune Effector Cells Of A Companion Animal That Express An Activating Receptor And Cells That Express B7-H3 And Uses Thereof
  • Compositions Comprising Polyglutamic Acid Nanoparticles And Cd40 Agonists
  • Pharmaceutical Composition For Treatment And/Or Prophylaxis Of Cancer
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Assay For Measurement Of Antibodies Binding To A Therapeutic Monoclonal Antibody
  • Pharmaceutical Compositions And Methods Useful For Modulating Angiogenesis, Inhibiting Metastasis And Tumor Fibrosis, And Assessing The Malignancy Of Colon Cancer Tumors
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Methods For Detecting Cancer Metastasis
  • Multiple Signaling Pathways Induced By Hexvalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • M-Csf-Specific Monoclonal Antibody And Uses Thereof
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Fusion Antibodies For Hiv Therapy
  • Methods And Compositions For Treatment And Diagnosis Of Fibrosis, Tumor Invasion, Angiogenesis, And Metastasis
  • Porphyromonas Gingivalis Polypeptides And Nucleotides
  • Anti-Mesothelin Antibodies
  • Antibodies Specific For Tgf-Beta And Methods For Treating Thereof
  • Neuritogenic Peptides
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Psca: Prostate Stem Cell Antigen And Uses Thereof
  • Method Of Diagnosing The Presence Of A Tumor In A Mammal By Assessing Cdo Expression Levels
  • B7-H3l Cell Surface Antigen And Antibodies That Bind Thereto
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Antibody Peg Positional Isomers, Compositions Comprising Same, And Use Thereof
  • Method Of Producing A Pigmented Composite Microporous Material
  • Anti-Mesothelin Antibodies
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus
  • Methods Of Decreasing Tumor Volume And Reducing Tumor Burden Using Tnf-Receptor-Coupling Agents
  • Her2/Neu-Specific Antibodies And Methods Of Using Same
  • Humanized Anti-Tag 72 Cc49 For Diagnosis And Therapy Of Human Tumors
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Antibodies And Pharmaceutical Compositions Containing Same Useful For Inhibiting Activity Of Metalloproteins
  • Hcv Antigen-Antibody Combination Assay And Methods And Compositions For Use Therein
  • Tetranectin-Apolipoprotein A-I, Lipid Particles Containing It And Its Use
  • Pd-1 Specific Antibodies And Uses Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Methods And Materials For Detecting C9orf72 Hexanucleotide Repeat Expansion Positive Frontotemporal Lobar Degeneration Or C9orf72 Hexanucleotide Repeat Expansion Positive Amyotrophic Lateral Sclerosis
  • Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
  • Combination Of Fcγriib-Specific Antibodies And Cd20-Specific Antibodies And Methods Of Use Thereof
  • Heterodimeric Proteins
  • Spliceostatin Analogs And Methods For Their Preparation
  • Fgf21 Mutants And Uses Thereof
  • Immuno-Pet Imaging Of Antibodies And Immunoconjugates And Uses Therefor
  • Anti Human Immunodeficiency Antibodies And Uses Thereof
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Antibodies Inhibiting C-Met Dimerization And Uses Thereof
  • Method For Treating Coronary Artery Disease Using Antibody Binding Human Protein Tyrosine Phosphatase Beta(Hptpbeta)
  • Modified Polynucleotides Encoding Copper Metabolism (Murr1) Domain Containing 1
  • Novel Antibodies For Conferring Passive Immunity Against Infection By A Pathogen In Humans
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Beta Secretase Polypeptides
  • Nucleic Acids Encoding Antibodies To Matrix Metalloproteinase 9
  • Antibodies To A Non-Ligand Binding Region Of At Least Two Notch Receptors
  • Composition And Method For Diversification Of Target Sequences
  • Antibodies That Bind To Repulsive Guidance Molecule A (Rgma)
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells
  • Antigen Binding Molecules With Increased Fc Receptor Binding Affinity And Effector Function
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Method To Generate Antibodies To Ion Channels
  • Humanized Anti-Factor D Antibodies
  • Hybrid Antibodies
  • Fgf-21 Mutants Comprising Polyethylene Glycol And Uses Thereof
  • Hybrid Antibodies
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Diagnosis And Treatment Of Viral Diseases
  • Therapeutic Canine Immunoglobulins And Methods Of Using Same
  • Microarrays And Uses Therefor
  • Peptides Directed For Diagnosis And Treatment Of Amyloid-Associated Diseases
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Anti-Ige Antibodies And Method Of Improving Polypeptides
  • Recombinant Materials For Producing Humanized Anti-Il-8 Antibodies
  • Antibodies Having Modified Carbohydrate Content And Methods Of Preparation And Use
  • Modified Antibodies
  • Novel Anti-Hiv Antibodies
  • Humanized Cdr-Grafted Anti-Icam-1 Antibodies, Methods Of Preparation And Usage Thereof
  • Recombinant Human Anti-Cd18 Antibodies
  • Coiled Coil And/Or Tether Containing Protein Complexes And Uses Thereof
  • Antibodies With Binding Affinity For The Cd3 Antigen
  • Method Of Using Humanized Antibody Against Cd18
  • Polynucleotides Which Encode Reshaped Il-8-Specific Antibodies And Methods To Produce The Same
  • Method Of Enhancing Proliferation Or Differentiation Of Hematopoietic Stem Cells Using Wnt Polypeptides
  • Epitope Which Binds To Monoclonal Antibody
  • Methods For The Production Of Proteins With A Desired Function
  • Non-Cross-Reactive Anti Igg Antibodies
  • Diagnosis And Treatment Of Viral Diseases
  • Bi-Specific Monovalent Diabodies That Are Capable Of Binding To Gpa33 And Cd3, And Uses Thereof
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Methods Of Inducing Or Enhancing An Immune Response In A Subject Having Cancer By Administering Gitr Antibodies
  • Anti-Alpha V Beta 6 Antibodies And Uses Thereof
  • Recognition Tags For Tgase-Mediated Conjugation
  • Methods Of Improving Vaccine Immunogenicity
  • Thrombin/Plasmin-Regulated Antibodies That Bind Tfpi
  • Anti-Ox40 Antibodies And Methods Of Use
  • Antibody Formulations
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Signal Biomarkers
  • Therapeutic Targets In Cancer
  • Three Dimensional Coordinates Of Hptpbeta
  • Human Monoclonal Antibodies Against Cd25
  • Anti-Ox40l Antibodies
  • Biological Products
  • Notch1 Receptor Binding Agents And Methods Of Use Thereof
  • Kid31 And Antibodies That Bind Thereto
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Methods For The Treatment Of Cancer Using Anti-Cd40 Antibodies
  • High Potency Recombinant Antibodies And Method For Producing Them
  • Methods And Compositions For Producing An Enhanced Immune Response To A Human Papillomavirus Immunogen
  • Polypeptide Inducing Apoptosis
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Methods Of Reducing Trail-Induced Apoptosis By Trail Isoforms
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Anti-Factor B Antibodies And Their Uses
  • Compositions And Methods To Inhibit Stem Cell And Progenitor Cell Binding To Lymphoid Tissue And For Regenerating Germinal Centers In Lymphatic Tissues
  • Antibodies To Vla-1
  • Antibody Molecules Specific To Human Tumour Necrosis Factor Alpha
  • Methods For Inhibiting Cell Proliferation
  • Gel Microdrop Composition And Method Of Using The Same
  • Anti-Cd26 Antibodies And Methods Of Use Thereof
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Tumor Necrosis Factor-Gamma
  • Method Of Treating Breast Cancer Using Anti-Her2 Antibody Variants
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Engineered Anti-Il-23 Antibodies
  • Humanized Anti-Amyloid Antibody
  • Methods For Producing Members Of Specific Binding Pairs
  • Antibodies That Bind To The C35 Polypeptide
  • Antibodies That Bind Human Protein Tyrosine Phosphatase Beta (Hptpβ)
  • Peptide Nanostructure-Coated Electrodes
  • Humanized Fcγriib-Specific Antibodies And Methods Of Use Thereof
  • Peptide Nanostructures Containing End-Capping Modified Peptides And Methods Of Generating And Using The Same
  • Methods For Producing Antibodies
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Methods And Compositions For Immunizing Against Chlamydia Infection
  • Trypanosoma Cruzi Proteome Compositions And Methods
  • In Vitro Methods Of Producing And Identifying Immunoglobulin Molecules In Eukaryotic Cells
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Apo-2 Receptor Polynucleotides
  • Hgf Beta Chain Variants
  • Methods For Producing Members Of Specific Binding Pairs
  • Variant Fc Regions
  • Antibodies To Gm-Csf
  • Cbh1 Homologs And Variant Cbh1 Cellulases
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Methods Of Ex Vivo Hematopoietic Stem Cell Expansion By Co-Culture With Mesenchymal Cells
  • Methods Of Screening For Agonists And Antagonists Of Patched-2
  • Anti-Vegf Antibodies
  • Method And Apparatus To Identify Vulnerable Plaques With Thermal Wave Imaging Of Heated Nanoparticles
  • Anti-Ngf Antibodies And Methods Using Same
  • Antibodies To Receptor Of Advanced Glycation End Products (Rage) And Uses Thereof
  • Methods For Producing Recombinant Proteins
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
  • Cdr-Repaired Antibodies
  • Ephb3-Specific Antibody And Uses Thereof
  • Degraded Tpo Agonist Antibody
  • Chimeric Ospa Genes, Proteins, And Methods Of Use Thereof
  • Chimeric Ospa Genes, Proteins, And Methods Of Use Thereof
  • Nucleic Acids Encoding B7rp1
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Humanized Anti-Fgf19 Antagonists And Methods Using Same
  • Mammalian Suv39h2 Proteins And Isolated Dna Molecules Encoding Them
  • Carrier Molecules
  • Use Of Modified Antibodies With Human Milk Fat Globule Specificity
  • Humanized Antibodies
  • Single-Chain Multiple Antigen-Binding Molecule, Its Preparation And Use
  • Immunotoxins Directed Against Cd33 Related Surface Antigens
  • Treatment For Inflammatory Bowel Disease With A Fibronectin Polypeptide
  • Oncogene- Or Virus-Controlled Expression Systems
  • Method Of Treating Allergic Disorders
  • Patched-2
  • Nucleic Acid Encoding Patched-2
  • Methods For Treating Cancer Using Psca Antibodies And Fragments Thereof
  • Methods Of Determining Cellular Chemosensitivity
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Fusion Proteins And Polynucleotides Encoding Gelonin Sequences
  • Hybridoma And Anti-Kc-4 Humanized Monoclonal Antibody
  • Humanized Antibodies Directed Against A33 Antigen
  • Biofilm Treatment
  • Plasmodium Falciparum-Infected Erythrocytes Binding To Icam-1 And Cd36
  • Humanized C-Erbb-2 Specific Antibodies
  • Humanized Interleukin-2 Receptors Antibodies
  • Monoclonal Antibodies Specific For Different Epitopes Of Human Gp39 And Methods For Their Use In Diagnosis And Therapy
  • Bgl6 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Albumin Binding Antibodies And Binding Fragments Thereof
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Ultrapurified Dsba And Dsbc And Methods Of Making And Using The Same
  • Antibodies That Specifically Bind Pms2
  • Recombinant Anti-Cd4 Antibodies For Human Therapy
  • Humanized Anti-Lymphotoxin Beta Receptor Antibodies
  • Expression Control Using Variable Intergenic Sequences
  • Antibodies Specific For Cd44v6
  • Method Of Producing Bispecific Molecules By Protein Trans-Splicing
  • Polynucleotides Encoding Antibodies Directed Against Amyloid-Beta Peptide
  • Covalent Diabodies And Uses Thereof
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Recombinant Anti-Cd4 Antibodies For Human Therapy
  • Nanoparticles Containing Polymeric Nucleic Acid Homologs
  • Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus
  • Antibodies To Receptor Of Advanced Glycation End Products (Rage) And Uses Thereof
  • Compositions And Methods For Growth Factor Modulation
  • Use Of Signal Enhancing Compounds In Electrochemiluminescence Detection
  • Methods Of Inhibiting Solid Tumor Growth By Administering Gpr49 Antibodies
  • Methods For Identifying Safe And Functional Humanized Antibodies
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Hydrazinyl-Pyrrolo Compounds And Methods For Producing A Conjugate
  • Human Control Antibodies And Uses Therefor
  • Fgf21 Mutants Comprising A Mutation At Position 98, 171 And/Or 180
  • Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Methods For Treating Progressive Multiple Sclerosis
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Human Antigen Binding Proteins That Bind Β-Klotho, Fgf Receptors And Complexes Thereof
  • Covalent Diabodies And Uses Thereof
  • Substituted Pyrazines As Cadherin-11 Inhibitors
  • Genetically Modified Human Natural Killer Cell Lines
  • Antibodies For The Treatment Of Hiv
  • Method For Treating Cancer Using An Antibody That Inhibits Notch4 Signaling
  • Cell Migration Assay
  • Humanized Chimeric Antibody Directed Against Ganglioside Gd3
  • Granulocyte-Binding Antibody Constructs, Their Preparation And Use
  • Humanized Antibodies Reactive With Gpiib/Iiia
  • Platelet-Specific Chimeric 7e3 Immunoglobulin
  • Monoclonal Antibodies Reactive With Tumor Proliferating Cells
  • Binding Constructs And Methods For Use Thereof
  • Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf) Neutralizing Antibodies
  • Formulation And Delivery Of Plga Microspheres
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Methods Of Reducing Level Of One Or More Impurities In A Sample During Protein Purification
  • Immunoglobulins And Variants Directed Against Pathogenic Microbes
  • System And Method For Oct Depth Calibration
  • Fgf Mutants With Reduced Proteolysis And Aggregation
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Control Of Rage Fusion Protein Glycosylation And Rage Fusion Protein Compositions
  • B7-H3l Cell Surface Antigen And Antibodies That Bind Thereto
  • Methods And Compositions Relating To Islet Cell Neogenesis
  • Anti-Herpes Simplex Virus Antibodies And Methods Of Use Thereof
  • Humanized Antibodies
  • Increasing Antibody Affinity By Altering Glycosylation Of Immunoglobulin Variable Region
  • Method For Producing Polymers Having A Preselected Activity
  • Methods For Treating Post-Exposure Rabies And Anti-Rabies Compositions
  • Variant Galactose Oxidase, Nucleic Acid Encoding Same, And Methods Of Using Same
  • Production Of Tnfr-Ig
  • Method Of Treatment With Antibodies Having Specificity For Human Ox40
  • Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes
  • Bacterially Derived, Intact Minicells Encompassing Regulatory Rna
  • Anti-Bv8 Antibodies And Uses Thereof
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Single Domain Antibodies Directed Against Tumor Necrosis Factor-Alpha And Uses Therefor
  • Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
  • Polynucleotides Encoding An Anti-Beta-Amyloid Monoclonal Antibody
  • Compositions And Methods Of Altering Cholesterol Levels
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Monoclonal Antibodies To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Anti-Cdh3 Humanized Antibody, Drug Conjugate Thereof, And Use Thereof
  • Anti-Cmet Antibody
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Combination Therapies Employing Gitr Binding Molecules
  • Anti-Cxcr4 Antibodies And Antibody-Drug Conjugates
  • Compositions And Methods Useful For Stabilizing Protein-Containing Formulations
  • Il-17 Binding Proteins
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Virtual Neonatal Echocardiographic Training System
  • Method Of Determining Virus Removal From A Sample Containing A Target Protein Using Activated Carbon
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Compositions And Methods For Growth Factor Modulation
  • Antibodies Against The Rgm A Protein And Uses Thereof
  • Methods Of Culturing And Expanding Mesenchymal Stem Cells
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Methods And Compositions For Modulating Hepsin Activation Of Macrophage-Stimulating Protein
  • Her2/Neu-Specific Antibodies And Methods Of Using Same
  • Anti-Cmet Antibody
  • Therapeutic Dll4 Binding Proteins
  • Humanized Anti-Cd40 Antibodies And Their Methods Of Use
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Monoclonal Antibody
  • Peptides And Methods Using Same For Diagnosis And Treatment Of Amyloid-Associated Disease
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Il-17 Binding Proteins
  • Anti-Notch3 Antibodies And Antibody-Drug Conjugates
  • Deimmunized Serum-Binding Domains And Their Use In Extending Serum Half-Life
  • Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer
  • Modified Polynucleotides Encoding Basic Helix-Loop-Helix Family Member E41
  • Anti-Ανβ6 Antibodies And Uses Thereof
  • Anti-Vegf Antibodies
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Interferon Alpha Receptor I Antibodies And Their Use
  • Lox And Loxl2 Inhibitors And Uses Thereof
  • Calcium Binding Recombinant Antibody Against Protein C
  • Anti-Cmet Antibody
  • Enrichment Method For Variant Proteins With Altered Binding Properties
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Anti Human Interleukin-1 Receptor Accessory Protein (Il1 Rap) Antibodies And Uses Thereof
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Cadherin-11 Inhibitors And Methods Of Use Thereof
  • Cytolethal Distending Toxin Subunit B Conjugated Or Fused To Bacillus Anthracis Toxin Lethal Factor
  • Prevention, Treatment And Diagnosis Of P. Gingivalis Infection
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Ror1-Binding Molecules, And Methods Of Use Thereof
  • Compositions Capable Of Specifically Binding Particular Human Antigen Presenting Molecule/Pathogen-Derived Antigen Complexes And Uses Thereof
  • Binding Moieties Based On Shark Ignar Domains
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Antibody Molecules Having Specificity For Human Ox40
  • Methods And Compositions For Assessing Responsiveness Of B-Cell Lymphoma To Treatment With Anti-Cd40 Antibodies
  • Hybrid Amyloid-Beta Antibodies
  • Antibodies To Receptor For Advanced Glycation End Products (Rage) And Uses Thereof
  • Multimeric Proteins And Methods Of Making And Using Same
  • Biomarkers For Detecting Cancer
  • Multispecific Binding Molecules Comprising Connecting Peptides
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Protective Antigen Of Group A Streptococci
  • Modified Polynucleotides For The Production Of Proteins
  • Method For Detecting Caprin-1 In A Biological Sample
  • Cell Detection
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Methods For Inducing Or Enhancing An Immune Response By Administering Agonistic Gitr-Binding Antibodies
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Vertebrate Smoothened Proteins
  • Catalytic Antibodies Against Cocaine
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Human Inkt Cell Activation Using Glycolipids
  • Agent For Treating Disease
  • Methods And Kits For Diagnosing Tumorigenicity And Determining Resistance To The Antineoplastic Effects Of Antiestrogen Therapy
  • Gitr Antigen Binding Proteins And Methods Of Use Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • High Throughput Generation And Affinity Maturation Of Humanized Antibody
  • Modified Pseudomonas Exotoxin A
  • Pharmaceutical Compositions Containing Sc(Fv)2
  • Notch1 Receptor Antibodies And Methods Of Treatment
  • Polynucleotides Encoding Notch Receptor Antibodies
  • Methods And Compositions For Inhibiting The Growth Of Hematopoietic Malignant Cells
  • Humanized Anti-Tag 72 Cc49 For Diagnosis And Therapy Of Human Tumors
  • Treatment With Anti-Alpha2 Integrin Antibodies
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • System For Antibody Expression And Assembly
  • Anti-Gd2 Antibodies
  • Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer
  • Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator Of Tumor Aggressiveness And Potential Therapeutic Target
  • Human Il-23 Antigen Binding Proteins
  • Intravascular Forward Imaging Device
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Anti-Her2 Antibody Variants
  • Methods Of Modulating Immune Function
  • Synthetic Peptide Constructs For The Diagnosis And Treatment Of Periodontis Associated With Porphyromonas Gingivalis
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Glycopeptide And Uses Thereof
  • Humanized Anti-Emap Ii Antibody And Use Thereof
  • Antimicrobial Compositions And Methods Of Use
  • Neutralizing Monoclonal Antibodies Against The Nogo-66 Receptor (Ngr) And Uses Thereof
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Liver Cancer
  • Il-18 Binding Protein (Il-18bp) And Antibodies In Inflammatory Diseases
  • Modified Hepatitis C Virus Proteins
  • Methods Of Treating Retinal Nerve Fiber Layer Degeneration With Monoclonal Antibodies Against A Retinal Guidance Molecule (Rgm) Protein
  • Bgl6 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Rsv-Specific Binding Molecules And Means For Producing Them
  • Immunoglobulin Variants And Uses Thereof
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Anti-C-Met Antibody
  • Anti-B7-H5 Antibodies And Their Uses
  • Biological Products
  • Compositions And Methods For Inhibiting Growth Of Smad4-Deficient Cancers
  • Inhibition And Treatment Of Prostate Cancer Metastasis
  • Anti-Cmet Antibody
  • Lowered Affinity Antibodies And Uses Therefor
  • Antibodies To Lymphotoxin-Α
  • Small Streptococcus Pyogenes Antigens And Their Use
  • Biomarkers
  • Pseudomonas Exotoxin A With Reduced Immunogenicity
  • Cd3-Binding Molecules Capable Of Binding To Human And Non-Human Cd3
  • Guidewire Artifact Removal In Images
  • Antibodies To Plasminogen Activator Inhibitor-1 (Pai-1) And Uses Thereof
  • Humanized Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator Of Tumor Aggressiveness And Potential Therapeutic Target
  • Method For Treating Psoriasis
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Modified Polynucleotides For The Production Of Oncology-Related Proteins And Peptides
  • Antigen Binding Proteins
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Monoclonal Antibodies To Growth And Differentiation Factor 15 (Gdf-15)
  • Determining The Capability Of A Test Compound To Affect Solid Tumor Stem Cells
  • High Affinity Nucleic Acid Ligands Of Complement System Proteins
  • Hepatitis C Antibodies And Uses Thereof
  • Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
  • Anti-Igf-Ir Antibodies And Uses Thereof
  • Safe And Functional Humanized Antibodies
  • Anti-Mpl Antibodies
  • Humanized Anti-Tgf-Beta Antibodies
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Humanized Anti-Tag-72 Monoclonal Antibodies
  • Reducing The Immunogenicity Of Fusion Proteins
  • Communications Network System And Methods For Using Same
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Antibodies Against Her3
  • Enzymatic Conjugation Of Polypeptides
  • Methods Of Use Of Anti-Cd19 Antibodies With Reduced Immunogenicity
  • Antibodies Against Tim3 And Uses Thereof
  • Staphylococcus Aureus Materials And Methods
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Methods For The Treatment Of Disease Using Immunoglobulins Having Fc Regions With Altered Affinities For Fcγractivating And Fcγrinhibiting
  • Humanized Anti-Cd4 Antibody With Immunosuppressive Properties
  • Compositions And Methods Relating To Universal Glycoforms For Enhanced Antibody Efficacy
  • Antibodies Against Claudin 18.2 Useful In Cancer Diagnosis
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • A Blocking Monoclonal Antibody To Vla-1 And Its Use For The Treatment Of Vascular Disorders
  • Immunotherapy Regimes Dependent On Apoe Status
  • Monoclonal Antibody That Binds Human Notch2 And Notch3
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus
  • Antibodies Which Bind B7rp1
  • Anti-Kc4 Humanized Monoclonal Antibody And Cells That Express The Antibody
  • Hybrid Antibodies
  • Anti-Axl Antibodies And Methods Of Use
  • Diagnostic Antibody Assay
  • Antibody Against Human Parathormone Related Peptides
  • Method Of Preventing The Onset Of Allergic Disorders
  • Apaf-1 An Activator Of Caspase-3
  • Method For Tapping The Immunological Repertiore
  • Method For Producing Polymers Having A Preselected Activity
  • Hepatocyte Growth Factor Receptor Agonists And Uses Thereof
  • O-Fucosyltransferase
  • Anti-Amyloid Antibodies And Uses Thereof
  • Antibodies To Matrix Metalloproteinase 9
  • Influenza Treatment And/Or Characterization, Human-Adapted Ha Polypeptides; Vaccines
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Proteins Comprising An Igg2 Domain
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Neuropilin Antagonists
  • Methods And Monitoring Of Treatment With A Dll4 Antagonist
  • Terminally Modified Rna
  • Spliceostatin Analogs And Methods For Their Preparation
  • Peptides Derived From Cytotoxicity Receptor Natural Killer Protein 44 Nkp44
  • Cancer Diagnosis And Imaging
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Human Protein Tyrosine Phosphatase Inhibitors And Methods Of Use
  • Antibodies Against Human Csf-1r
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Isolation And Use Of Solid Tumor Stem Cells
  • Methods For Viral Inactivation And Other Adventitious Agents
  • Gitr Antibodies And Methods Of Inducing Or Enhancing An Immune Response
  • Endoglin Antibodies
  • Anti-Mesothelin Antibodies
  • Pharmaceutical Composition For Treating Cancer Using A Monoclonal Antibody Having Immunological Reactivity With Caprin-1
  • Anti Notch-1 Antibodies
  • Humanized Antibody Or Fragment Thereof Specific For Cd45r0
  • Methods Of Making Antibody Heavy And Light Chains Having Specificity For A Desired Antigen
  • Combination Therapy With Co-Stimulatory Factors
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Antibody Therapy
  • Neutralizing Monoclonal Antibodies Against The Nogo-66 Receptor (Ngr)
  • Anti-Vegf Antibodies
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Compositions And Methods For Treating And Diagnosing Cancer
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Β-Glucosidase 5 (Bgl5) Compositions
  • Methods And Compositions For Modulating T Helper (Th) Cell Development And Function
  • Antibodies That Bind Il-18 And Methods Of Inhibiting Il-18 Activity
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Anti-Dll4 Antibodies And Methods Using Same
  • Human Monoclonal Antibodies To Ctla-4
  • Monoclonal Antibody Capable Of Binding To Specific Discontinuous Epitope Occurring In Ad1 Region Of Human Cytomegalovirus Gb Glycoprotein, And Antigen-Binding Fragment Thereof
  • Kid3 And Kid3 Antibodies That Bind Thereto
  • Antibodies To Stra6 Polypeptides
  • Methods For Augmenting An Immune Response Using Anti-Cd40 Antibodies
  • Methods Of Expanding Stem And Progenitor Cells And Expanded Cell Populations Obtained Thereby
  • Anti-Fc-Gamma Riib Receptor Antibody And Uses Therefor
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Binding Moieties Based On Shark Ignar Domains
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • O-Fucosyltransferase
  • C5-Specific Antibodies For The Treatment Of Inflammatory Diseases
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Antiidiotypic Antibodies For High Molecular Weight-Melanoma Associated Antigen
  • Dnas Encoding Chimeric Immunoglobulin Light Or Heavy Chains And Fragments Thereof Having Variable Regions Derived From Monoclonal Antibody 7e3, And Vectors And Host Cells Comprising Same
  • Proteins Encoding Gelonin Sequences
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Uses Of Wnt Polypeptides
  • Apo-2 Ligand
  • Targeted Forms Of Methyltrithio Antitumor Agents
  • Cytotoxic Drug Therapy
  • Humanized Antibodies
  • Nucleic Acids Encoding Antigen-Binding Sites Specific For Cancer Antigens
  • Optimization Of Binding Proteins
  • Production Of Chimeric Antibodies - A Combinatorial Approach
  • Polynucleotides Encoding Gelonin Sequences
  • Production Of A Multimeric Protein By Cell Fusion Method
  • Compositions And Methods For Detecting And Quantifying Host Cells Protein In Cell Lines And Recombinant Polypeptide Products
  • Anti-Theophylline Antibodies And Methods Of Use
  • Protein Purification Methods To Remove Impurities
  • Culturing Of Mesenchymal Stem Cells With Fgf4 And Nicotinamide
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • System For Antibody Expression And Assembly
  • Anti-Gd2 Antibodies
  • Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer
  • Locating Intravascular Images
  • Chimeric Ospa Genes, Proteins And Methods Of Use Thereof
  • Modified Polynucleotides For The Production Of Cosmetic Proteins And Peptides
  • Stabilized Liquid Anti-Rsv Antibody Formulations
  • Agents For Treating Disease
  • Anti-Her2 Glycoantibodies And Uses Thereof
  • Self-Assembled Fmoc-Ff Hydrogels
  • Methods Of Treating Ulcerative Colitis
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Method For Inhibiting The Immune Suppressive Function Of Human T Regulatory Cells By Administering An Anti-Garp Monoclonal Antibody
  • Immunoglobulins And Variants Directed Against Pathogenic Microbes
  • Immunological Targeting Of Pathological Tau Proteins
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Recombinant Antibodies For Human Therapy
  • Modified Antibody Variable Domains
  • Nucleic Acids Encoding Hepatocyte Growth Factor Receptor Antagonist Antibodies
  • Recombinant Human Anti-Lk26 Antibodies
  • Recombinant Antibodies For Human Therapy
  • Purified Immunoglobulin
  • Recombinant Antibodies For Human Therapy
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Apo-3 Polypeptide
  • Glycosyl-Etoposide Prodrugs, A Process For Preparation Thereof And The Use Thereof In Combination With Functionalized Tumor-Specific Enzyme Conjugates
  • Antibodies Which Activate An Erythropoietin Receptor
  • Isoforms Of Human Pregnancy-Associated Protein-E
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Interleukin-5 Specific Recombinant Antibodies
  • Egviii Endoglucanase And Nucleic Acids Encoding The Same
  • Anti-Ige Antibodies
  • Humanized Antibody Against Human Tissue Factor (Tf) And Process Of Production Of The Humanized Antibody
  • Thermomyces Lanuginosus Kinesin Motor Protein And Methods Of Screening For Modulators Of Kinesin Proteins
  • Psca: Prostate Stem Cell Antigen And Uses Thereof
  • Methods Of Optimizing Antibody Variable Region Binding Affinity
  • Monoclonal Antibodies (Mabs) Against Tumor-Associated Antigens, The Preparation And Use Thereof
  • Il-2 Fusion Proteins With Modulated Selectivity
  • Antibodies That Bind To Cancer-Associated Antigen Cd46 And Methods Of Use Thereof
  • Treatment For Inflammatory Bowel Disease With Α4-Specific Antibodies
  • Induction Of Cytotoxic T Lymphocyte Responses Using Anti-Cd40 Antibodies
  • Production Of Polypeptides
  • Variants Of Humanized Anti-Carcinoma Monoclonal Antibody Cc49
  • Anti-Alphabeta3 Humanized Monoclonal Antibodies
  • Egviii Endoglucanase And Nucleic Acids Encoding The Same
  • Biological Products
  • Monoclonal Antibodies (Mabs) Against Tumor-Associated Antigens, The Preparation And Use Thereof
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Methods Of Optimizing Antibody Variable Region Binding Affinity
  • Thermomyces Lanuginosus Kinesin Motor Protein And Methods Of Screening For Modulators Of Kinesin Proteins
  • Interleukin-5 Specific Recombinant Antibodies
  • Macrophage Derived Chemokine (Mdc) And Chemokine Analogs And Assay To Identify Modulators Of Mdc Activity, And Therapeutic Uses For Same
  • Psca: Prostate Stem Cell Antigen And Uses Thereof
  • Method For Reducing The Immunogenicity Of Antibody Variable Domains
  • Glycosyl-Etoposide Prodrugs, A Process For Preparation Thereof And The Use Thereof In Combination With Functionalized Tumor-Specific Enzyme Conjugates
  • Isoforms Of Human Pregnancy-Associated Protein-E
  • C5-Specific Antibodies For The Treatment Of Inflammatory Diseases
  • Production Of Anti-Abeta
  • Production Of Polypeptides
  • Variants Of Humanized Anti-Carcinoma Monoclonal Antibody Cc49
  • Modified Anti-Cd52 Antibody
  • Bgl4 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Compositions And Methods Relating To Universal Glycoforms For Enhanced Antibody Efficacy
  • Protein Purification Methods To Remove Impurities
  • Anti-Her2 Glycoantibodies And Uses Thereof
  • Self-Assembled Fmoc-Ff Hydrogels
  • Methods Of Treating Ulcerative Colitis
  • Method For Inhibiting The Immune Suppressive Function Of Human T Regulatory Cells By Administering An Anti-Garp Monoclonal Antibody
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Agents For Treating Disease
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Immunological Targeting Of Pathological Tau Proteins
  • Apo-3 Polypeptide
  • Glycosyl-Etoposide Prodrugs, A Process For Preparation Thereof And The Use Thereof In Combination With Functionalized Tumor-Specific Enzyme Conjugates
  • Catecholic Butanes And Use Thereof For Cancer Therapy
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Therapeutic Uses Of The Hypervariable Region Of Monoclonal Antibody M195 And Constructs Thereof
  • Hybridoma And Anti-Kc-4 Humanized Monoclonal Antibody, Dna And Rna Encoding It, Kit, Diagnostic And Therapeutic Methods
  • Immunoconjugates And Humanized Antibodies Specific For B-Cell Lymphoma And Leukemia Cells
  • Antibodies Which Bind B7rp1
  • Anti-Kc4 Humanized Monoclonal Antibody And Cells That Express The Antibody
  • Identification And Expression Of A Novel Kinesin Motor Protein
  • Antibodies To C-Met
  • Antibodies To Human Tumor Necrosis Factor Receptor-Like 2
  • Antigen Pipa And Antibodies That Bind Thereto
  • Entropic Bristle Domain Sequences And Their Use In Recombinant Protein Production
  • Compositions And Methods For Restoring Sensitivity Of Tumor Cells To Antitumor Therapy And Inducing Apoptosis
  • Cd40 Ligand Adjuvant For Respiratory Syncytial Virus
  • Anti-Angiogenic Compounds
  • Trimeric Collagen Scaffold Antibodies
  • Biomarkers
  • Beta Secretase Genes
  • Angiogenesis Inhibiting Molecules, Their Selection, Production And Their Use In The Treatment Of Cancer
  • Vegfr-3 Fusion Proteins
  • Anti-Αvβ3 Humanized Monoclonal Antibodies
  • Immunotherapy Regimes Dependent On Apoe Status
  • Monoclonal Antibody That Binds Human Notch2 And Notch3
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Methods For Purifying A Target Protein From One Or More Impurities In A Sample
  • Methods To Determine Immunogenicity Of Humanized Anti-Tag 72 Cc49 Antibodies
  • Met-Binding Agents And Uses Thereof
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Shortened Tetranectin-Apolipoprotein A-1 Fusion Protein, A Lipid Particle Containing It, And Uses Thereof
  • Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
  • Compositions And Methods For The Treatment Of Tumor Of Hematopoietic Origin
  • Anti-Pcsk9 Antibodies, Formulations, Dosing, And Methods Of Use
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Il-18 Binding Proteins
  • Proteins Comprising An Igg2 Domain
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Anti-Amyloid Antibodies And Uses Thereof
  • Chimeric Antigen Receptor Specific For Folate Receptor Β
  • Peptides And Methods Using Same For Diagnosis And Treatment Of Amyloid-Associated Disease
  • Neuropilin Antagonists
  • Anti Notch-1 Antibodies
  • Endoglin Antibodies
  • Anti-Mesothelin Antibodies
  • Pharmaceutical Composition For Treating Cancer Using A Monoclonal Antibody Having Immunological Reactivity With Caprin-1
  • Medicament For Treating And/Or Preventing Cancer
  • Signal Biomarkers
  • B7rp-1 Antagonists
  • Humanized Anti-Fgf19 Antagonists And Methods Using Same
  • Antibodies Against Human Epo Receptor
  • In Vivo Production Of Proteins
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Genetically Modified Human Natural Killer Cell Lines
  • Il-17 Binding Proteins
  • Protein Formulation
  • Enhancing Activity Of Car T Cells By Co-Introducing A Bispecific Antibody
  • Anti-Human Igg1 Antibody
  • Antibody Constructs For Cdh19 And Cd3
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Modified Polynucleotides Encoding Siah E3 Ubiquitin Protein Ligase 1
  • Humanized Immunoglobulins And Their Production And Use
  • Rnai Vitamin D Conjugates
  • Methods For Treating Melanoma
  • Glypican-3-Specific Antibody And Uses Thereof
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Blocking Il-9 Signaling In Conjunction With Chemotherapy To Treat Cancer
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Binding Moieties Based On Shark Ignar Domains
  • Engineered Anti-Il-23 Antibodies
  • Neuritogenic Peptides
  • Inhibition And Treatment Of Prostate Cancer Metastasis
  • Antibodies To Human Tumor Necrosis Factor Receptor-Like 2
  • Antigen Pipa And Antibodies That Bind Thereto
  • Humanized Immunoglobulins
  • Entropic Bristle Domain Sequences And Their Use In Recombinant Protein Production
  • Beta Secretase Genes
  • Use Of A Decoy Protein That Interferes With The Hedgehog Signalling Pathway For The Manufacture Of A Medicament For Preventing, Inhibiting, And/Or Reversing Ocular Diseases Related With Ocular Neovascularization
  • Genetically Modified Human Natural Killer Cell Lines
  • Angiogenesis Inhibiting Molecules, Their Selection, Production And Their Use In The Treatment Of Cancer
  • Trimeric Collagen Scaffold Antibodies
  • Anti-Αvβ3 Humanized Monoclonal Antibodies
  • Compositions And Methods For Restoring Sensitivity Of Tumor Cells To Antitumor Therapy And Inducing Apoptosis
  • Cd40 Ligand Adjuvant For Respiratory Syncytial Virus
  • Modulation Of T Cell Differentiation For The Treatment Of T Helper Cell Mediated Diseases
  • Vegfr-3 Fusion Proteins
  • Humanized Antibody Specific For Tumor Necrosis Factor-Alpha
  • Methods And Compositions Comprising Purified Recombinant Polypeptides
  • Anti-Pcsk9 Antibodies, Formulations, Dosing, And Methods Of Use
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Cancer
  • Met-Binding Agents And Uses Thereof
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Shortened Tetranectin-Apolipoprotein A-1 Fusion Protein, A Lipid Particle Containing It, And Uses Thereof
  • Methods And Reagents For Detecting Bioactive Lipids
  • Heterodimeric Antibodies To Cd3 X Cd20
  • Production Of Motif-Specific And Context-Independent Antibodies Using Peptide Libraries As Antigens
  • Compositions And Methods For The Treatment Of Tumor Of Hematopoietic Origin
  • Therapeutic Dll4 Binding Proteins
  • Methods For Purifying A Target Protein From One Or More Impurities In A Sample
  • Methods To Determine Immunogenicity Of Humanized Anti-Tag 72 Cc49 Antibodies
  • Il-18 Binding Proteins
  • Modified Polynucleotides Encoding Hepatitis A Virus Cellular Receptor 2
  • Therapeutic Composition For Treatment Of Glioblastoma
  • Pulmonary Administration Of Immunoglobulin Single Variable Domains And Constructs Thereof
  • Antibodies Against Human Epo Receptor
  • In Vivo Production Of Proteins
  • Genetically Modified Human Natural Killer Cell Lines
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Stable Igg4 Based Binding Agent Formulations
  • Method And Apparatus To Identify Vulnerable Plaques With Thermal Wave Imaging Of Heated Nanoparticles
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Antibodies To Carcinoembryonic Antigen (Cea), Methods Of Making Same, And Uses Thereof
  • Intranasal Administration Of Active Agents To The Central Nervous System
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Zanamivir Phosphonate Congeners With Anti-Influenza Activity And Determining Oseltamivir Susceptibility Of Influenza Viruses
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Carriers For Improved Drug Delivery
  • Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
  • Calicheamicin Derivative-Carrier Conjugates
  • 5-Hydroxymethylcytosine In Human Cancer
  • Covalent Diabodies And Uses Thereof
  • Pd-1 Specific Antibodies And Uses Thereof
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Humanized Antibodies To Ganglioside Gm2
  • Antigen-Binding Sites Of Antibody Molecules Specific For Cancer Antigens
  • Combining Anti-Hla-Dr Or Anti-Trop-2 Antibodies With Microtubule Inhibitors, Parp Inhibitors, Bruton Kinase Inhibitors Or Phosphoinositide 3-Kinase Inhibitors Significantly Improves Therapeutic Outcome In Cancer
  • Anti-Tissue Factor Antibodies And Compositions
  • Bispecific Anti-Vegf/Anti-Ang-2 Antibodies
  • Optical-Electrical Rotary Joint And Methods Of Use
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Anti-Cd38 Human Antibodies And Uses Thereof
  • Crosslinking Of Cd22 By Epratuzumab Triggers Bcr Signaling And Caspase-Dependent Apoptosis In Hematopoietic Cancer Cells
  • Formulation For Anti-Α4Β7 Antibody
  • Polynucleotides Encoding Notch1 Receptor Antibodies
  • Immunology Treatment For Biofilms
  • Calicheamicin Derivative-Carrier Conjugates
  • Kid3 And Kid3 Antibodies That Bind Thereto
  • Cd37 Immunotherapeutics And Uses Thereof
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Porphyromonas Gingivalis Polypeptides And Nucleotides
  • Cell Death-Inducing Agent
  • Antibodies And Other Molecules That Bind B7-H1 And Pd-1
  • Methods And Compositions For Immunizing Against Chlamydia Infection
  • Mucosal Vascular Addressins And Uses Thereof
  • Kid31 And Antibodies That Bind Thereto
  • Il-1 Binding Proteins
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Dual Variable Domain Immunoglobulin And Uses Thereof
  • Methods Of Treating Diabetes And Compositions Capable Of Same
  • Il-D80 Polynucleotides
  • Methods For Generating Monovalent Igg
  • Compositions Of Psma Antibodies
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Method For Making Humanized Antibodies
  • Cancerous Disease Modifying Antibodies
  • Erbb3 Binding Antibody
  • Antibody Therapy
  • Hgf Β Chain Variants
  • Autocrine Growth Factor Receptor Antibodies And Methods
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Chimeric Antibody Against Tumor Associated Antigens And Its Use In Diagnosing Tumors
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid
  • Methods To Increase Or Decrease Bone Density
  • Uses Of A Chemokine Receptor Able To Bind To Mcp-1, Mip-1Α And/Or Rantes
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Systems And Methods For Narrowing A Wavelength Emission Of Light
  • Abeta Conformer Selective Anti-Abeta Globulomer Monoclonal Antibodies
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Method Of Treating Cancer By Administering Csf-1r Antibodies And A Tlr9 Agonist
  • Modified Polynucleotides For The Production Of Proteins
  • Stirred Tank Bioreactor
  • Anti-Cd19 Antibodies With Reduced Immunogenicity
  • Anti-Nerve Growth Factor Antibodies And Methods Of Preparing And Using The Same
  • Human Antibodies That Bind Human Madcam
  • Binding Domains Of Proteins Of The Repulsive Guidance Molecule (Rgm) Protein Family And Functional Fragments Thereof, And Their Use
  • Il-17 Binding Proteins
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Infectious Clone Of Human Parvovirus B19 And Methods
  • Il-1 Binding Proteins
  • Methods Of Improving Stem Cell Homing And Engraftment
  • Prostaglandin E2 Dual Variable Domain Immunoglobulins And Uses Thereof
  • Fcγriib Specific Antibodies And Methods Of Use Thereof
  • Notch1 Receptor Binding Agents And Methods Of Use Thereof
  • Anti-Il-12/Il-23 Antibodies
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Glycosylation Engineering Of Antibodies For Improving Antibody-Dependent Cellular Cytotoxicity
  • Il-I Binding Proteins
  • Method For Screening For An Anti-Cd4 Antibody Suitable For Use In Immunotherapy
  • Prevention And Treatment Of Amyloidogenic Disease
  • Binding Compounds For Il-27
  • Glycosyl-Etoposide Prodrugs, A Process For Preparation Thereof And The Use Thereof In Combination With Functionalized Tumor-Specific Enzyme Conjugates
  • Detecting Lipocalin
  • Natural Human Antibody
  • Trichoderma Β-Glucosidase
  • Separate-Cistron Contructs For Secretion Of Aglycosylated Antibodies From Prokaryotes
  • Anti-Ige Antibodies
  • Production Of Humanised Antibodies To Tnfα
  • Autocrine Growth Factor Receptor Antibodies And Methods
  • Zanamivir Phosphonate Congeners With Anti-Influenza Activity And Determining Oseltamivir Susceptibility Of Influenza Viruses
  • Methods For Diagnosing And Treating Inflammatory Bowel Disease
  • Anti-Fzd10 Monoclonal Antibodies And Methods For Their Use
  • Cd36 Immunoadhesins And Their Use In Selectively Killing Plasmodium Falciparum Infected Erythrocytes
  • Improvements In Or Relating To Antibodies
  • Chimeric Immunoglobulins Specific For P55 Tac Protein Of The Il-2 Receptor
  • Lo-Cd2a Antibody And Uses Thereof For Inhibiting T Cell Activation And Proliferation
  • Humanized Immunoglobulins And Their Production And Use
  • Anti-Cd74 Immunoconjugates And Methods
  • Anti-Pd-L1 Antibodies, Compositions And Articles Of Manufacture
  • Dosages For Treatment With Anti-Erbb2 Antibodies
  • Method And Means For Site Directed Therapy
  • Antibodies To Vla-1
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
  • Human Monoclonal Antibodies Against Cd25
  • Combination Therapy With Anti-Hla-Dr Antibodies And Kinase Inhibitors In Hematopoietic Cancers
  • Rsv-Specific Binding Molecules And Means For Producing Them
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Methods Of Producing Two Chain Proteins In Bacteria
  • Rsv-Specific Binding Molecule
  • Caninized Anti-Nerve Growth Factor Antibodies
  • Endoglin Antibodies
  • Human Anti-Pd-1, Pd-L1, And Pd-L2 Antibodies And Uses Therefor
  • Methods Of Treating Of Diabetes And Obesity Using Fgf21 Mutants
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Generating Targeted Sequence Diversity In Fusion Proteins
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Glycan Conjugates And Use Thereof
  • Compositions And Methods For Treatment And Detection Of Cancers
  • Altered Antibodies And Their Preparation
  • Aβ Conformer Selective Anti-Aβ Globulomer Monoclonal Antibodies
  • Covalent Diabodies And Uses Thereof
  • Bh3 Peptides And Methods Of Use Thereof
  • Cell Culture Compositions With Antioxidants And Methods For Polypeptide Production
  • Antigenic Gm-Csf Peptides And Antibodies To Gm-Csf
  • Bifunctional Cytotoxic Agents
  • Anti-Sortilin Antibodies And Methods Of Use Thereof
  • Recombinant Human Anti-Cd18 Antibodies
  • Reshaped Monoclonal Antibodies Against An Immunoglobulin Isotype
  • Nsp4 Inhibitors And Methods Of Use
  • Compositions And Methods For Treatment And Detection Of Cancers
  • Cytotoxicity-Inducing Theraputic Agent
  • Cd3-Binding Molecules Capable Of Binding To Human And Non-Human Cd3
  • Cell Culture Media And Methods Of Antibody Production
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Antibodies And Derivatives Thereof
  • Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes
  • Method For Reduction Of 1->2 Reading Frame Shifts
  • Methods For Stimulating Hematopoietic Recovery By Inhibiting Tgfβ Signaling
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Methods Of Identifying Agents That Modulate The Binding Between Mdc And An Mdc Receptor
  • Nucleic Acid Constructs For The Cell Cycle-Regulated Expression Of Genes And Therapeutic Methods Utilizing Such Constructs
  • Monoclonal Antibodies Against Tumor-Associated Antigens, Processes For The Preparation Thereof And The Use Thereof
  • Therapeutic Dll4 Binding Proteins
  • Biomarkers
  • Homeobox Gene
  • Human Alpha-Folate Receptor Chimeric Antigen Receptor
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • Benzocyclooctyne Compounds And Uses Thereof
  • Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
  • Filipil Compositions And Methods For Treating Cancer
  • Magneto-Motive Ultrasound Detection Of Magnetic Nanoparticles
  • Muc1 Antibodies
  • Ilt3 Binding Molecules And Uses Therefor
  • Antibodies To Tgf-Β
  • Rsv Specific Binding Molecule
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Enzymatic Conjugation Of Polypeptides
  • Enhanced Protein Purification Through A Modified Protein A Elution
  • Pharmaceutical Composition For Treatment And/Or Prevention Of Gallbladder Cancer
  • Multivalent Antibodies And Uses Therefor
  • Use Of Anti-Cd83 Agonist Antibodies For Treating Autoimmune Diseases
  • Antibody Fc Variants
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Fully Human, Anti-Mesothelin Specific Chimeric Immune Receptor For Redirected Mesothelin-Expressing Cell Targeting
  • Dna Encoding Antibody Molecules Which Bind Il-17a And Il-17f
  • Endoglin Antibodies
  • Antibody Therapy
  • Chimeric Fibroblast Growth Factors With Altered Receptor Specificity
  • Human Antibody Specific To Toxin Produced From Clostridium Difficile, Or Antigen-Binding Fragment Thereof
  • Humanized Anti-Cd4 Antibody With Immunosuppressive Properties
  • Immunoaffinity Isolation Of Modified Peptides From Complex Mixtures
  • Chimeric Il-1 Receptor Type I Antagonists
  • Method Of Treating An Ischemia-Reperfusion Injury-Related Disorder By Administering Gpcr Ligands
  • Method Of Treating Cancer By Administering A Monoclonal Antibody That Binds Human Notch2 And Notch3
  • Modified Polynucleotides Encoding Aquaporin-5
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Specific Antibodies Against Human Cxcl4 And Uses Thereof
  • Human Monoclonal Antibodies To Ctla-4
  • Neuropilin Antagonists
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Insulin Vitamin D Conjugates
  • Anti-Ceacam5 Antibodies And Uses Thereof
  • Production Of A Multimeric Protein By Cell Fusion Method
  • Methods, Compositions And Apparatuses For Detection Of Gamma-Hydroxybutyric Acid (Ghb)
  • Method Of Treatment Using Humanized Anti-Cd11a Antibodies
  • Methods And Compositions Of Matter Concerning April/G70, Bcma, Blys/Agp-3 And Taci
  • Cytokine Receptor And Nucleic Acids Encoding The Same
  • 88kda Tumorigenic Growth Factor And Antagonists
  • Drosophila G Protein Coupled Receptors, Nucleic Acids, And Methods Related To The Same
  • Cd3 Specific Recombinant Antibody
  • Anti-Ige Antibodies
  • Apo-2li And Apo-3 Polypeptides
  • Treatment For Inflammatory Bowel Disease With A Vcam-1/1gg Fusion Protein
  • Target Cell-Specific Non-Viral Vectors For Inserting Genes Into Cells, Pharmaceutical Compositions Comprising Such Vectors And Their Use
  • Antigen-Binding Sites Of Antibody Molecules Specific For Cancer Antigens
  • Mn-Specific Antibodies And Their Use In Cancer Treatment
  • Method Of Antithrombotic Therapy Using Anti-Gpiib/Iiia Antibodies Or Fragments Thereof, Including C7e3
  • Humanized Antibody Against Cd18
  • Method To Treat Inflammation With Humanized Anti-Il-8-Antibodies
  • Transferrin Receptor Specific Antibody-Neuropharmaceutical Or Diagnostic Agent Conjugates
  • Uses Of Antibodies To Aminophospholipids For Cancer Treatment
  • Nucleic Acid Constructs Containing Hybrid Promoters
  • Treatment Of Inflammatory Bowel Disease By Inhibiting Binding And/Or Signalling Through Α 4 Β 7 And Its Ligands And Madcam
  • Production Of Anti-Self Antibodies From Antibody Segment Repertories And Displayed On Phage
  • Methods Of Modulating Lipid Metabolism And Storage
  • In Vitro Scanning Saturation Mutagenesis Of Proteins
  • Specific Binding Agents
  • Recombinant Cdr-Grafted And Chimeric Anti-Il-8 Antibodies Containing Cdrs Or The Variable Region From The Mouse Monoclonal Antibody, Ws-4
  • Minimum Recognition Unit Of A Pem Mucin Tandem Repeat Specific Monoclonal Antibody And Detection Method Using Same
  • Modified Antibodies With Human Milk Fat Globule Specificity
  • Polynucleotides Encoding The Anti-Pem Antibody Bw835 Variable Domains And Expression Vectors
  • Reagents For Generating A Polyclonal Hydrolytic Antibody Response Against Cocaine And The Monoclonal Hydrolytic Antibodies Against Cocaine Derived Through These Reagents
  • Prevention And Treatment Of Amyloidogenic Disease
  • Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
  • Conjugate Of An Antibody Against Ccr5 And An Antifusogenic Peptide
  • Expansion Of Renewable Stem Cell Populations
  • Stra6 Polypeptides
  • Antibodies Directed Against Amyloid-Beta Peptide
  • Anti-Neoplastic Uses Of Artemin Antagonists
  • Methods And Compositions For Decreasing T-Cell Activity
  • Variable Domain Library And Uses
  • Gpr30 Estrogen Receptor In Breast Cancers
  • Therapeutic Targets In Cancer
  • Apo-2 Receptor Agonist Antibodies
  • Tumor Necrosis Factor-Gamma
  • Microarray And Uses Therefor
  • Receptor Coupling Agents And Compositions Thereof
  • Anti-Cmet Antibodies
  • Reshaped Human Anti-Hm 1.24 Antibody
  • Polynucleotides Encoding Antibodies That Bind To The C35 Polypeptide
  • Heterodimeric Fusion Proteins Useful For Targeted Immune Therapy And General Immune Stimulation
  • Peptides Which Bind To G Protein-Coupled Receptors
  • Treatment Of Cerebral Amyloid Angiopathy
  • Identification And Engineering Of Antibodies With Variant Fc Regions And Methods Of Using Same
  • Junctional Adhesion Molecule-C (Jam-C) Binding Compounds And Methods Of Their Use
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Feeding Formula Appliance
  • Synthetic Antibody Phage Libraries
  • Method For Tapping The Immunological Repertoire
  • Method For Using Antibodies For Inhibiting Blood Coagulation
  • Deimmunized Monoclonal Antibodies For Protection Against Hiv Exposure And Treatment Of Hiv Infection
  • Biological Products
  • Humanized Anti-Erbb2 Antibodies And Treatment With Anti-Erbb2 Antibodies
  • Chimeric Anti-Vegf-D Antibodies And Humanized Anti-Vegf-D Antibodies And Methods Of Using Same
  • Immunocytokine Sequences And Uses Thereof
  • Covalent Diabodies And Uses Thereof
  • Antibodies That Bind To The C35 Polypeptide
  • Peptides, Derivatives And Analogs Thereof, And Methods Of Using Same
  • Method Of Humanizing Antibodies By Matching Canonical Structure Types Cdrs
  • Anti-Vegf Antibodies
  • Methods For Producing Members Of Specific Binding Pairs
  • Compositions And Methods In Cancer Associated With Altered Expression Of Kcnj9
  • Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
  • Humanized Antibodies
  • Transferrin Receptor Specific Antibody-Neuropharmaceutical Or Diagnostic Agent Conjugates
  • Antigen-Binding Sites Of Antibody Molecules Specific For Cancer Antigens
  • Mn-Specific Antibodies And Their Use In Cancer Treatment
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Lo-Cd2a Antibody And Uses Thereof For Inhibiting T Cell Activation And Proliferation
  • Antibodies To Vla-1
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Method And Means For Site Directed Therapy
  • Glycosyl-Etoposide Prodrugs, A Process For Preparation Thereof And The Use Thereof In Combination With Functionalized Tumor-Specific Enzyme Conjugates
  • Anti-Cxcr4 Antibodies And Their Use For The Treatment Of Cancer
  • Compositions And Methods For Diagnosing And/Or Treating Influenza Infection
  • Methods For The Treatment Of Disease Using Immunoglobulins Having Fc Regions With Altered Affinities For Fcγractivating And Fcγrinhibiting
  • Anti-Vegf Antibodies
  • Polypeptide Constructs Including Vhh Directed Against Egfr For Intracellular Delivery
  • Antibodies That Bind To Epha2 And Methods Of Use Thereof
  • Recombinant Prion-Like Proteins And Materials Comprising Same
  • Compositions And Methods In Cancer Associated With Altered Expression Of Prlr
  • Bgl4 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Methods And Compositions For Increasing Antibody Production
  • Bgl6 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Cd36 Immunoadhesins And Their Use In Selectively Killing Plasmodium Falciparum Infected Erythrocytes
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Methods For Producing Members Of Specific Binding Pairs
  • Compositions Capable Of Specifically Binding Particular Human Antigen Presenting Molecule/Pathogen-Derived Antigen Complexes And Uses Thereof
  • Split Dose Administration
  • Immunoaffinity Isolation Of Modified Peptides From Complex Mixtures
  • Assembly Of Bispecific Antibodies
  • Pharmaceutical Composition For Treatment And/Or Prophylaxis Of Cancer
  • Treating A Mammal With A Formulation Comprising An Antibody Which Binds Ige
  • Anti-A(Β) Oligomer Humanized Antibody
  • Anti-Fzd10 Monoclonal Antibodies And Methods For Their Use
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Anti-Gd2 Antibodies
  • Human Monoclonal Antibodies To Ctla-4
  • Humanized Antibodies That Bind Lgr5
  • Treatment Of Allergic Diseases With Recombinant Antibodies
  • Anti-Siglec-8 Antibodies And Methods Of Use Thereof
  • Psma Antibodies And Uses Thereof
  • Antibodies Against Human Cd39 And Use Thereof For Inhibiting T Regulatory Cells Activity
  • Antibody Therapy
  • Rsv-Specific Binding Molecules And Means For Producing Them
  • Psma Antibodies And Uses Thereof
  • Anti-Biotin Antibodies And Methods Of Use
  • Methods Of Determining Patient Response By Measurement Of Her-3 And P95
  • Antibodies That Bind The Glutamate Ligand Binding Region Of Notch3
  • Anti-Vegf Antibodies
  • Insulin Vitamin D Conjugates
  • Anti-Ceacam5 Antibodies And Uses Thereof
  • Anti Ceacam1 Antibodies And Methods Of Using Same
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Adam-9 Modulators
  • Bispecific Antigen Binding Proteins
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Cancer Therapy
  • Antibodies Against Human Csf-1r And Uses Thereof
  • Multispecific Antibodies Comprising Full Length Antibodies And Single Chain Fab Fragments
  • Antibody For The Diagnosis And/Or Prognosis Of Cancer
  • Dual Specific Binding Proteins Directed Against Il-13 And Il-17
  • Modified Polynucleotides Encoding Aryl Hydrocarbon Receptor Nuclear Translocator
  • Antigen-Presenting Complex-Binding Compositions And Uses Thereof
  • Genetically Modified Human Natural Killer Cell Lines
  • Use Of Complement Inhibitors To Treat Ocular Diseases
  • Antibody Capable Of Specifically Recognizing Transferrin Receptor
  • Method Of Treatment Of A Solid Tumor With Interleukin-1 Accessory Protein Antibody
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Systems And Methods For Generating Images Of Tissue
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Covalently-Associated Diabody Complexes That Possess Charged Coil Domains And That Are Capable Of Enhanced Binding To Serum Albumin
  • Method For Detecting Pancreatic Cancer
  • Hepatitis C Antibodies And Uses Thereof
  • Vegf/Dll4 Binding Agents And Uses Thereof
  • Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
  • Removal Of A-Scan Streaking Artifact
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Human Monoclonal Antibodies Against Cd25
  • Il-1 Binding Proteins
  • Therapeutic Dll4 Binding Proteins
  • B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of Cancer
  • B7-H1 Antibodies And Method Of Use
  • Method For Controlling The Activity Of Immunologically Functional Molecule
  • Methods Of Treating With Anti-Factor D Antibodies
  • Fgf21 Mutants And Uses Thereof
  • Anti-Ox40l Antibodies
  • Method For Making Heteromultimeric Molecules
  • Method To Generate Antibodies To Ion Channels
  • Dual Specific Binding Proteins Directed Against Il-1Β And/Or Il-17
  • Antibodies Inhibiting C-Met Dimerization, And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Co-Use Of A Clusterin Inhibitor With An Egfr Inhibitor To Treat Cancer
  • Bispecific Antibodies That Bind To Cd38 And Cd3
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Angiogenesis Inhibiting Molecules, Their Selection, Production And Their Use In The Treatment Of Cancer
  • Tri- Or Tetraspecific Antibodies
  • Nucleic Acid Molecules Encoding A Humanized Antibody
  • Calicheamicin Derivative-Carrier Conjugates
  • Bgl5 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Identification And Expression Of A Novel Kinesin Motor Protein
  • Rage Fusion Proteins And Methods Of Use
  • Antibodies Against Claudin 18.2 Useful In Cancer Diagnosis
  • Il-17 Binding Proteins
  • Humanized Anti Cxcr4 Antibodies For The Treatment Of Cancer
  • Anti-Spla2-Iia Antibodies And Uses Thereof
  • Engineered Anti-Il-23p19 Antibodies
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Anti-Cd74 Immunoconjugates And Methods
  • Multimodal Segmentation In Intravascular Images
  • Nucleic Acids Encoding Antibodies Against Human Csf-1r
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Human M2e Peptide Immunogens
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Antibodies Against Human Parathyroid Hormone Related Protein
  • Antibodies To Madcam
  • Recombinant Protein Production In A Human Cell Comprising At Least One E1 Protein Of Adenovirus
  • Methods For Producing Members Of Specific Binding Pairs
  • Humanised Antibody Against Hepatitis
  • Anti-Vegf Antibodies
  • Formulation And Delivery Of Plga Microspheres
  • Polynucleotides Encoding Anti-Cd20 Antigen Binding Molecules With Increased Fc Receptor Binding Affinity And Effector Function
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Stabilizer For Protein Preparation Comprising Meglumine And Use Thereof
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Fgf21 Polypeptides Comprising Two Or More Mutations And Uses Thereof
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Il-17 Binding Proteins
  • Production Of Secreted Therapeutic Antibodies In Microalgae
  • Methods Of Diagnosing Acute Cardiac Disorders Using Bnp-Sp
  • Methods For Treating Bone Cancer By Administering A Nerve Growth Factor Antagonist Antibody
  • Humanized Antibodies That Recognize Beta Amyloid Peptide
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/332323a0

    DOI

    http://dx.doi.org/10.1038/332323a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1016704652

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3127726


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amino Acid Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Binding Sites, Antibody", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Genes, Synthetic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin G", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Heavy Chains", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Light Chains", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Variable Region", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recombinant Fusion Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recombinant Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Species Specificity", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "MRC Laboratory of Molecular Biology", 
              "id": "https://www.grid.ac/institutes/grid.42475.30", 
              "name": [
                "MRC Laboratory of Molecular Biology, Cambridge, UK."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Riechmann", 
            "givenName": "L", 
            "id": "sg:person.01266242006.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266242006.84"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Clark", 
            "givenName": "M", 
            "id": "sg:person.011120724612.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120724612.52"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Waldmann", 
            "givenName": "H", 
            "id": "sg:person.0633233513.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633233513.49"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Winter", 
            "givenName": "G", 
            "id": "sg:person.0655407005.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655407005.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/256495a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001387921", 
              "https://doi.org/10.1038/256495a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.166.5.1351", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005737479"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/321522a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007617918", 
              "https://doi.org/10.1038/321522a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.83.16.6075", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009328462"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000441-194312000-00015", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010564544"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000441-194312000-00015", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010564544"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/00000441-194312000-00015", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010564544"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1146/annurev.me.34.020183.000543", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012510385"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(85)90137-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016089018"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(80)90168-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016442666"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(82)90183-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017559045"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/nar/14.4.1779", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017735770"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/312643a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017996216", 
              "https://doi.org/10.1038/312643a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/328731a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018042438", 
              "https://doi.org/10.1038/328731a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/328731a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018042438", 
              "https://doi.org/10.1038/328731a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(80)90252-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020340850"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(87)90412-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021276801"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.84.10.3439", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022927453"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.163.6.1539", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023028745"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.81.22.7161", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024498868"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.74.12.5463", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025360556"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/314268a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027818224", 
              "https://doi.org/10.1038/314268a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1432-1033.1974.tb03576.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029928612"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.81.21.6851", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030102558"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(87)90242-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031976560"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(87)90242-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031976560"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/300709a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042192921", 
              "https://doi.org/10.1038/300709a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0065-2776(08)60009-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045714057"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0378-1119(83)90230-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048250339"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.78.4.2072", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051147601"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830171104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051609518"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7326/0003-4819-101-4-579_3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1073689567"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1988-03", 
        "datePublishedReg": "1988-03-01", 
        "description": "A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. The reshaped human antibody is as effective as the rat antibody in complement and is more effective in cell-mediated lysis of human lymphocytes.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/332323a0", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0090-0028", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6162", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "332"
          }
        ], 
        "name": "Reshaping human antibodies for therapy", 
        "pagination": "323-327", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "4f97482e4af8baf2cbfaadbf94f1b233086e496e398c3b63a90424376cd5b65b"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3127726"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0410462"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/332323a0"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1016704652"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/332323a0", 
          "https://app.dimensions.ai/details/publication/pub.1016704652"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T20:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000424.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://www.nature.com/nature/journal/v332/n6162/full/332323a0.html"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/332323a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/332323a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/332323a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/332323a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    245 TRIPLES      21 PREDICATES      74 URIs      38 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/332323a0 schema:about N0f39243fee8b4e8c87760d76faf0f891
    2 N1123f23b2b3a49f08002b225e593ad30
    3 N159e24bbea194964897a85bd3806eaac
    4 N1b95e89d734c44a5928f096bf2d1c458
    5 N36d1d7c6512247e8bfe77b67bed14e69
    6 N522e60935be549b0aa05beec9c37c471
    7 N88acb46ab3934e4ba4aef1faf09ac509
    8 N94e50714782b4f138ee8ba5bd1650873
    9 Na5002d9bed364971b885f442fa48100f
    10 Na67ab0271f5f4d179e36cb21718142bd
    11 Nb336b7611db3482988839d15f38ccc07
    12 Nc704f1e3285247d0a350c398c8e7aca6
    13 Ncd4e400838bc47ec996b6d13ca561042
    14 Nd47fe352bf2140dcaa2c5c147676317a
    15 Nd5067a5c44e949c9bd9a5dea283483b9
    16 Nf0d0b1285e4f4c29aae0d16ffa1f88f8
    17 Nf357e5504a6d4306a507441f642e2eea
    18 anzsrc-for:11
    19 anzsrc-for:1107
    20 schema:author N83befdea03e945998fbe1361b12aa8d5
    21 schema:citation sg:pub.10.1038/256495a0
    22 sg:pub.10.1038/300709a0
    23 sg:pub.10.1038/312643a0
    24 sg:pub.10.1038/314268a0
    25 sg:pub.10.1038/321522a0
    26 sg:pub.10.1038/328731a0
    27 https://doi.org/10.1002/eji.1830171104
    28 https://doi.org/10.1016/0022-1759(87)90242-0
    29 https://doi.org/10.1016/0022-2836(80)90252-1
    30 https://doi.org/10.1016/0022-2836(85)90137-8
    31 https://doi.org/10.1016/0022-2836(87)90412-8
    32 https://doi.org/10.1016/0092-8674(80)90168-3
    33 https://doi.org/10.1016/0092-8674(82)90183-0
    34 https://doi.org/10.1016/0378-1119(83)90230-5
    35 https://doi.org/10.1016/s0065-2776(08)60009-7
    36 https://doi.org/10.1073/pnas.74.12.5463
    37 https://doi.org/10.1073/pnas.78.4.2072
    38 https://doi.org/10.1073/pnas.81.21.6851
    39 https://doi.org/10.1073/pnas.81.22.7161
    40 https://doi.org/10.1073/pnas.83.16.6075
    41 https://doi.org/10.1073/pnas.84.10.3439
    42 https://doi.org/10.1084/jem.163.6.1539
    43 https://doi.org/10.1084/jem.166.5.1351
    44 https://doi.org/10.1093/nar/14.4.1779
    45 https://doi.org/10.1097/00000441-194312000-00015
    46 https://doi.org/10.1111/j.1432-1033.1974.tb03576.x
    47 https://doi.org/10.1146/annurev.me.34.020183.000543
    48 https://doi.org/10.7326/0003-4819-101-4-579_3
    49 schema:datePublished 1988-03
    50 schema:datePublishedReg 1988-03-01
    51 schema:description A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. The reshaped human antibody is as effective as the rat antibody in complement and is more effective in cell-mediated lysis of human lymphocytes.
    52 schema:genre research_article
    53 schema:inLanguage en
    54 schema:isAccessibleForFree true
    55 schema:isPartOf N5bf003c1cc2947c3ae83b9efe3de3291
    56 N66d417f63615437f83e140f44b473be0
    57 sg:journal.1018957
    58 schema:name Reshaping human antibodies for therapy
    59 schema:pagination 323-327
    60 schema:productId N0635bd85a11b4e99b9d92afdf27cc3b5
    61 N549548053b4446b2a7864cc72a2b5c2d
    62 N8620c0d84f7f4badbf84421b90bb6a95
    63 Na032acf4615a4e7abd9ecc46f9b7c309
    64 Nf336fd6e51e04fa89e7ceb392b3b720f
    65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016704652
    66 https://doi.org/10.1038/332323a0
    67 schema:sdDatePublished 2019-04-10T20:34
    68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    69 schema:sdPublisher N20597ac20d6047a8aa9a6b1d07ff08a9
    70 schema:url http://www.nature.com/nature/journal/v332/n6162/full/332323a0.html
    71 sgo:license sg:explorer/license/
    72 sgo:sdDataset articles
    73 rdf:type schema:ScholarlyArticle
    74 N0635bd85a11b4e99b9d92afdf27cc3b5 schema:name dimensions_id
    75 schema:value pub.1016704652
    76 rdf:type schema:PropertyValue
    77 N0f39243fee8b4e8c87760d76faf0f891 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    78 schema:name Immunoglobulin Light Chains
    79 rdf:type schema:DefinedTerm
    80 N1123f23b2b3a49f08002b225e593ad30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    81 schema:name Base Sequence
    82 rdf:type schema:DefinedTerm
    83 N159e24bbea194964897a85bd3806eaac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    84 schema:name Lymphocytes
    85 rdf:type schema:DefinedTerm
    86 N1b95e89d734c44a5928f096bf2d1c458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    87 schema:name Antibodies, Monoclonal
    88 rdf:type schema:DefinedTerm
    89 N20597ac20d6047a8aa9a6b1d07ff08a9 schema:name Springer Nature - SN SciGraph project
    90 rdf:type schema:Organization
    91 N27617516995d42f4a3cd6713da94bca4 rdf:first sg:person.011120724612.52
    92 rdf:rest N8d0109b5b79e4c3991cc69cb6e447c7a
    93 N36d1d7c6512247e8bfe77b67bed14e69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    94 schema:name Humans
    95 rdf:type schema:DefinedTerm
    96 N522e60935be549b0aa05beec9c37c471 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Amino Acid Sequence
    98 rdf:type schema:DefinedTerm
    99 N549548053b4446b2a7864cc72a2b5c2d schema:name readcube_id
    100 schema:value 4f97482e4af8baf2cbfaadbf94f1b233086e496e398c3b63a90424376cd5b65b
    101 rdf:type schema:PropertyValue
    102 N5bf003c1cc2947c3ae83b9efe3de3291 schema:issueNumber 6162
    103 rdf:type schema:PublicationIssue
    104 N66d417f63615437f83e140f44b473be0 schema:volumeNumber 332
    105 rdf:type schema:PublicationVolume
    106 N83befdea03e945998fbe1361b12aa8d5 rdf:first sg:person.01266242006.84
    107 rdf:rest N27617516995d42f4a3cd6713da94bca4
    108 N8620c0d84f7f4badbf84421b90bb6a95 schema:name nlm_unique_id
    109 schema:value 0410462
    110 rdf:type schema:PropertyValue
    111 N88acb46ab3934e4ba4aef1faf09ac509 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Immunoglobulin G
    113 rdf:type schema:DefinedTerm
    114 N8d0109b5b79e4c3991cc69cb6e447c7a rdf:first sg:person.0633233513.49
    115 rdf:rest Nd97a094f0d0f4f76863d35f0708838b8
    116 N94e50714782b4f138ee8ba5bd1650873 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Molecular Sequence Data
    118 rdf:type schema:DefinedTerm
    119 Na032acf4615a4e7abd9ecc46f9b7c309 schema:name doi
    120 schema:value 10.1038/332323a0
    121 rdf:type schema:PropertyValue
    122 Na5002d9bed364971b885f442fa48100f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Genes, Synthetic
    124 rdf:type schema:DefinedTerm
    125 Na67ab0271f5f4d179e36cb21718142bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Rats
    127 rdf:type schema:DefinedTerm
    128 Nb336b7611db3482988839d15f38ccc07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Binding Sites, Antibody
    130 rdf:type schema:DefinedTerm
    131 Nc704f1e3285247d0a350c398c8e7aca6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Species Specificity
    133 rdf:type schema:DefinedTerm
    134 Ncd4e400838bc47ec996b6d13ca561042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Immunoglobulin Heavy Chains
    136 rdf:type schema:DefinedTerm
    137 Nd47fe352bf2140dcaa2c5c147676317a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Recombinant Proteins
    139 rdf:type schema:DefinedTerm
    140 Nd5067a5c44e949c9bd9a5dea283483b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Immunoglobulin Variable Region
    142 rdf:type schema:DefinedTerm
    143 Nd97a094f0d0f4f76863d35f0708838b8 rdf:first sg:person.0655407005.55
    144 rdf:rest rdf:nil
    145 Nf0d0b1285e4f4c29aae0d16ffa1f88f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Recombinant Fusion Proteins
    147 rdf:type schema:DefinedTerm
    148 Nf336fd6e51e04fa89e7ceb392b3b720f schema:name pubmed_id
    149 schema:value 3127726
    150 rdf:type schema:PropertyValue
    151 Nf357e5504a6d4306a507441f642e2eea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Animals
    153 rdf:type schema:DefinedTerm
    154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    155 schema:name Medical and Health Sciences
    156 rdf:type schema:DefinedTerm
    157 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    158 schema:name Immunology
    159 rdf:type schema:DefinedTerm
    160 sg:journal.1018957 schema:issn 0090-0028
    161 1476-4687
    162 schema:name Nature
    163 rdf:type schema:Periodical
    164 sg:person.011120724612.52 schema:familyName Clark
    165 schema:givenName M
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011120724612.52
    167 rdf:type schema:Person
    168 sg:person.01266242006.84 schema:affiliation https://www.grid.ac/institutes/grid.42475.30
    169 schema:familyName Riechmann
    170 schema:givenName L
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266242006.84
    172 rdf:type schema:Person
    173 sg:person.0633233513.49 schema:familyName Waldmann
    174 schema:givenName H
    175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633233513.49
    176 rdf:type schema:Person
    177 sg:person.0655407005.55 schema:familyName Winter
    178 schema:givenName G
    179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655407005.55
    180 rdf:type schema:Person
    181 sg:pub.10.1038/256495a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001387921
    182 https://doi.org/10.1038/256495a0
    183 rdf:type schema:CreativeWork
    184 sg:pub.10.1038/300709a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042192921
    185 https://doi.org/10.1038/300709a0
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1038/312643a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017996216
    188 https://doi.org/10.1038/312643a0
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1038/314268a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027818224
    191 https://doi.org/10.1038/314268a0
    192 rdf:type schema:CreativeWork
    193 sg:pub.10.1038/321522a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007617918
    194 https://doi.org/10.1038/321522a0
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1038/328731a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018042438
    197 https://doi.org/10.1038/328731a0
    198 rdf:type schema:CreativeWork
    199 https://doi.org/10.1002/eji.1830171104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051609518
    200 rdf:type schema:CreativeWork
    201 https://doi.org/10.1016/0022-1759(87)90242-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031976560
    202 rdf:type schema:CreativeWork
    203 https://doi.org/10.1016/0022-2836(80)90252-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020340850
    204 rdf:type schema:CreativeWork
    205 https://doi.org/10.1016/0022-2836(85)90137-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016089018
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1016/0022-2836(87)90412-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021276801
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1016/0092-8674(80)90168-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016442666
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1016/0092-8674(82)90183-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017559045
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1016/0378-1119(83)90230-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048250339
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1016/s0065-2776(08)60009-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045714057
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1073/pnas.74.12.5463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025360556
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1073/pnas.78.4.2072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051147601
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1073/pnas.81.21.6851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030102558
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1073/pnas.81.22.7161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024498868
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1073/pnas.83.16.6075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009328462
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1073/pnas.84.10.3439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022927453
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1084/jem.163.6.1539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023028745
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1084/jem.166.5.1351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005737479
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1093/nar/14.4.1779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017735770
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.1097/00000441-194312000-00015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010564544
    236 rdf:type schema:CreativeWork
    237 https://doi.org/10.1111/j.1432-1033.1974.tb03576.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029928612
    238 rdf:type schema:CreativeWork
    239 https://doi.org/10.1146/annurev.me.34.020183.000543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012510385
    240 rdf:type schema:CreativeWork
    241 https://doi.org/10.7326/0003-4819-101-4-579_3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073689567
    242 rdf:type schema:CreativeWork
    243 https://www.grid.ac/institutes/grid.42475.30 schema:alternateName MRC Laboratory of Molecular Biology
    244 schema:name MRC Laboratory of Molecular Biology, Cambridge, UK.
    245 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...